var title_f3_58_4000="Interdigital scabies PI";
var content_f3_58_4000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies between the fingers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scabies often affects the webs of the fingers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4000=[""].join("\n");
var outline_f3_58_4000=null;
var title_f3_58_4001="Pediatric hip fracture treatment";
var content_f3_58_4001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Delbet type III fracture after operative fixation with cannulated screws",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ten year old girl who fell from a tree. She required arthrotomy, open reduction, and internal fixation with cannulated screws.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Klane White, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4001=[""].join("\n");
var outline_f3_58_4001=null;
var title_f3_58_4002="CobraPLA";
var content_f3_58_4002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    CobraPLA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This device consists of a ventilation tube with a flexible \"cobra\"-shaped head at its distal end and a ventilation port at its proximal end.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission. Copyright &copy; 2012 Pulmodyne, Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4002=[""].join("\n");
var outline_f3_58_4002=null;
var title_f3_58_4003="Bakers cyst PI";
var content_f3_58_4003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Baker's cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 532px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIUAhoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBkkqRsiuwBc4XPc0+uU+Ily9hp2nXyHC29/C0n+4Wwf6V1dJPWw2tEwooopiCiiigAooooAKKKKACiiigAooooAKKKKACq+oXcVjbNPcOEjBAJPvViuL+LMjL4agjQ4aa9hj/M//AFqmT5U2VFc0kjtByKKBwKKokKKKKACs/XNZ0/QrIXerXK21uXEYdgTlj0AABOa0K4P4g3nma34YtkPyx6vbs31w39P50AaX/CwvDH/QT/8AJeX/AOJpi/EXwqzsi6spdfvKIJcj6/LXW1yMW60+KE6k4ivdOEg93Rwv8qmUuWxUY3uSf8LC8Mf9BP8A8l5f/iaP+FheGP8AoJ/+S8v/AMTXVUVRJyv/AAsLwx/0E/8AyXl/+Jo/4WF4Y/6Cf/kvL/8AE11VFAHK/wDCwvDH/QT/APJeX/4mmN8RfCqsFbVlDHnHkS5/9Brra5rVj/xUsXtAP5tQBX/4WN4UyP8AibLk9P3Ev/xNIfiP4TGc6uo/7YS//E1K/E1jnrn/ANlqpqQH7/8AP/x2gB5+JnhAddajH/bGT/4mk/4Wd4O/6DcP/fqT/wCJrkNTJCdaxmc8c15H9pv+U71g01uelr8SvCLfd1mM/SKT/wCJp3/CxvCh/wCYsv8A34l/+JrmtDB2pXU23ahZm27cpLwiXUYPiJ4WP/MVH/fiX/4mg/ETwqP+YqP+/Ev/AMTWpH92o5ia6HjGlexkqF3a5nf8LG8Kf9BZf+/Ev/xNH/Cx/Cn/AEFl/wC/Ev8A8TUkhOaidjiuZ5o07cpqsIu4H4j+Ex/zF1/78S//ABNJ/wALJ8Jd9YT/AL8y/wDxNULmRgDXP6hcuAcHrTWaX+yP6n5nZ/8ACwvC/wD0E/8AyXl/+Jpf+FheGP8AoJ/+S8v/AMTXUoNqKPQYpa9c4Tlf+FheGP8AoJ/+S8v/AMTR/wALC8Mf9BP/AMl5f/ia6qigDlf+FheGP+gn/wCS8v8A8TR/wsLwx/0E/wDyXl/+JrqqKAOUb4h+F1Us2qAKBkkwS8f+O0ifETws6hk1UMpGQRBLg/8Ajta/iuTyvC+ruOq2kpH/AHwaZ4N/5FPRs9TaRH81FTze9ylcvu8xm/8ACwvDH/QT/wDJeX/4mj/hYXhj/oJ/+S8v/wATXVUVRJyv/CwvDH/QT/8AJeX/AOJpr/ETwsisz6qFVRkkwSgAf9811lZXiz/kVdZ/68pv/QDQBo280dzbxTwOHilUOjDoykZBqSsrwn/yKujf9eUP/oArVoAKKKKACiiigAooooAKKKKACiiigDmviRa/avA+sIBykBmH/ACG/pWvod19u0Wwus586BJPzUGpNWtheaXeWp6TQvH+akf1rnPhVdG58C6cH/1kAaBh6FWIH6YqNpl7w+Z1tFFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcR8TsSt4atuvm6tDkeoGc/wA67euI8afv/G/g61HOJ5Zz/wABUGoqfCXT+I7eiiirICiiigCC+uFtLSSZv4RwPU9hXl+uu0mseHHc5ZtYgJPv81dh4ou986WyH5U+Zvr/APq/nXG6z/yFPDX/AGF4P/ZqAPWa5LxgRZeIvDGpdALprNz6iVcDP4iutrlviZaPc+ELuSH/AF1qVuUPoUOSfyzWdX4G+36F0/iSOpoqtpl2l/p1rdx/cniWUfQjP9as1onfUjYKKKKACua1UZ8Sp/17j+bV0tcvqLZ8Ryt/chA/TP8AWgBkp/0izHtn/wAdFVdRIAm/z/DVhvmvIAe0RP6AVUvWzHcfVh+gFJuyuBymqnCGsWMGSQfWtjVziM1l6cN0g+tfKHuo67REwi10lsOBWHpSbY1rdtxwKdPWRlMvIeKjn6U5ajnau6b905orUpydahk6VK3Wo5BxXmvc6kZd2eDXO3Y3zov95wP1roL3o1YsS+Zq9kn96dB/48KuCu0h7I9fooor6w8UKKKKACiiigDD8ctt8H6wf+nZx+YxUvhAY8J6KP8Apyh/9AFVfiAceC9X5x+4I/UVd8KqV8MaOpGCLOEf+OCsv+XnyNP+XfzNSiiitTMKyvFn/Iq6z/15Tf8AoBrVrK8Wf8irrP8A15Tf+gGgA8J/8iro3/XlD/6AK1ayvCf/ACKujf8AXlD/AOgCtWgAooooAKKKKACiiigAooooAKKKKACuH+Gv+iXfibSun2XUXdB6I/I/lXcVxOmKbL4s6vF0S+sI7n6sjBP8aiW6ZcNU0dtRRRVkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXE3qfafi7p69RaaY830LOVrtq43Qv8ASviV4juOotoLe2B+o3H9aifRFw6vyOyoooqyAqG9uFtbWSZ+ijgep7Cpq5nxReb5ltUPyp8zfXt/n3oAxJZGlkaRzlmOSfesfWf+Qp4a/wCwvB/7NWrWVrP/ACFPDX/YXg/9moA9ZqK7gS6tZreUZjlQxsPYjBqWigDkvhlNJ/wjj2Fx/r9OuZLR/facj9Gx+FdbXIaaw0z4i6nZZxFqVsl4g7b1JVgPc9a6+s6Xw27aGlT4r9wooorQzCuUvW3azfsOdoA/8dFdXXHwsZL69f8AvXBUH23f4CgCXrfSHsiAfmf/AK1YOvXYt7eIA/PPKqj/AIE2T+lbsnEFww++7iMfl/8AXrhfENz9p8T2lqhykByQPX/9QFZ1XaEn5HZgaPtqqT2Wr+RFrTfLiodGj3MPrTtWO6THvV3Q4ehNfLdD0eh09iu1VFa8A4rOtF4FakIwtaUVdmFRkoPFQTHNTE4FV5Dmtqj0sZxWpAaa3SnNSHpXEzcyb4cGsjTl3eIdOH/Twh/JhWxf96y9JH/FSaf/ANdl/nW1H416hL4WerUUUV9UeMFFFFABRRRQBzPxKYL4H1Y5/gUfm61saEnl6Jp6H+G3jH/jornviw2PA96oODI8S/X51P8ASusiQRxIg6KAKyX8R+i/U0f8Ner/AEH0UUVqZhWV4s/5FXWf+vKb/wBANatZXiz/AJFXWf8Arym/9ANAB4T/AORV0b/ryh/9AFatZXhP/kVdG/68of8A0AVq0AFFFFABRRRQAUUUUAFFFFABRRRQAVxvij/QvHfhe/6JMZbJz/vLlR+ddlXFfFhWi8OW2oRjL6dew3Qx7HH/ALNUVPhuXT+K3c7WimxSLLEkiHKuoYH1Bp1WQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcZ8OWFzdeJ74c+dqkkYPqqAAfzrrruZbe1mmfhY0Zz9AM1yPwjhZPBNtM/37qWWdvxcj+gqH8SRa+Fs7OiiirIIbydbW2kmfogzj1PYVwksjSyNI5yzHJPvW54pvN0iWqHhfmf69h/n1rAoAKytZ/5Cnhr/sLwf+zVq1laz/yFPDX/AGF4P/ZqAPWaKKKAOM+IP/Evu9C15eBY3QjmI/55ScMf8+tdn16VleKdNGr+HtQscZaaIhP94cr+oFQ+Cb/+0vCmmXJJLmEI5PXcvyt+oNZLSbXf+v8AI0esE+xt0UUVqZjJpBFC8h6IpY/hXH6MG8mAseXLO35f/Xrpddk8vSLs+sZUfU8D+dYNqmyLYpwRGIx9WNAEN7OtvZCWT5UVXnb8c4rzbRd11rE10/XDOfxPSun8e6iFi+xxHmU7eOyL/ic1z/hxcWt1N/efYPwH/wBeuXGy5aMj6HLqPssJOu95aL0JLkeZc/jW9o8O1OlY1tGZLjmuqsItsYr5xmTNG1XpWiowAKqW64xV1a3orQ56jGvUD1LIeahenVYRIj1pDQaQmuQ1MzUB1rN0dceI9PP/AE2Fat+MoTWZpZxr+n5/57r/ADraj8cfVBL4Weo0UUV9UeMFFFFABRRRQBxnxT+fRLCDj9/qEMf8z/Suzri/iHmXUfC1sOj6mjn/AID/APrrtKyh8cvkaS+CPzCiiitTMKyvFn/Iq6z/ANeU3/oBrVrK8Wf8irrP/XlN/wCgGgA8J/8AIq6N/wBeUP8A6AK1ayvCf/Iq6N/15Q/+gCtWgAooooAKKKKACiiigAooooAKKKKACsnxXYf2n4a1Ozxlpbdwo/2sZH6gVrUUmrqw07O5znw7vzqPgvSZ2OXEIiY+6fKf5V0dcV8NkFhP4i0Y8Gzv2kQekcgBX+RrtamD91FVFaTCiiirICiiigAooooAKKKKACiiigAooooA5/4gXf2LwXrEwOD9nZAfdvlH86s+D7T7D4V0m3xgpbR7h7lQT+pNYHxa3S+HLWxT719fQ2/5kn/2Wu1RQiKqjAAwBULWbLekELUN5OtrbSTP0QZx6nsKmrm/FN3udLVDwvzP9ewqyDCmkaaV5JDl2JJNMoooAKytZ/5Cnhr/ALC8H/s1atZWs/8AIU8Nf9heD/2agD1miiigArjvAzmy1jxHoz/KLe7NxEvpHLyAPYf1rsa43U/+Jb8TNLuvuxalavav6bk+Yf0FZVNGpef5mkNU4nZUUUVqZmJ4pk/0a3tweZpRkf7I5P64rLknEcW4deXH8hUuuS+frDKhyLeMIP8Afb/62K57xXfCysZNjfMfkT69B/U/hQXTpyqTUI7s43W7v7XqM82con7tPoP/AK+av6aBBo0IPWTLn8Tx+mK564Oy3Cjr0ro2UgQ26/8ALNVT8hivMzOVoKPdn2WYRVChToR2X6GhpUO5t1dJbjGBWZpsOyMcVr26c14m7PEbLsQ6VZHAqGMYxUrHC11U9Ec8tSNzzUL08mo2rKo7lxQw1GxqQ9KhbvWBoVZ/mjasuxG3XdPJ/wCfhP5itVfmDj3rJnPkX9tKeBHMj/kwNa03aSYNXTR6lRRRX1Z4wUUUUAFFFFAHH+JgZ/HvhSAfdT7RM34IMfyrsK467UzfFaxX+GDS2l+mXK/4V2NZU95Pz/RGk9oryCiiitTMKyvFn/Iq6z/15Tf+gGtWsrxZ/wAirrP/AF5Tf+gGgA8J/wDIq6N/15Q/+gCtWsrwn/yKujf9eUP/AKAK1aACiiigAooooAKKKKACiiigAooooAKKKranewabp11fXbFLa1ieeVgCSEUFicDrwDQByUr/ANl/FeLjEOr2OzPrLGSf/Qf5121eRfETxbbS2mk6zZ6XryyaddJP5kmlTopibhhuK45+Wuxj8dWMkavHpPiNkYAqRo9wQQf+AVEdG0XLVJnWUVyv/Cb2n/QH8Sf+Ca4/+IpD44swMnSPEmP+wNcf/EVZB1dFcaPiHpZUMNN8Q4Izn+yLjp/3zVeb4n6HCcS2evKffSZx/wCy0pSUdWxpN7HdUVw1v8TdFuP9TY6+/wDu6TOf/ZatDx9p5GRpfiMj/sD3H/xNSqkHsx8sl0Ovorjj8QtNB50zxEP+4Rcf/E1G/wASNIjHz6f4gX66TP8A/E0vaw7oOSXY7WiuSh8d2E0SyRaV4jdGGQw0e4IP/jlP/wCE3tP+gP4k/wDBNcf/ABFabknVUVyv/Cb2n/QH8Sf+Ca4/+Io/4Te0/wCgP4k/8E1x/wDEUAV/Fv8ApnjTwpp45CSyXrj02L8v6k12VeS2njG2u/ideXf9l688NlYLbBV0qcsrswblduRxnrXYf8Jvaf8AQH8Sf+Ca4/8AiKiPVlz2SOlu51traSZ/uoM/X2rg55WmmeWQ5ZySanuvFVrrrzWdnFewPalTPHd2zwOCwyvyuAcYqrVkBRRRQAVlaz/yFPDX/YXg/wDZq1aytZ/5Cnhr/sLwf+zUAes0UUUAFcj8RkEVppOo9DY6hDKx/wBgtgj9RXXVyvxQ2/8ACDakG6nywv18xcVnW+Bl0vjR1VMnkWGF5ZDhEUsx9AKcmdi7vvY5rD8WXO21jtFbDTn5/ZByf6D8a0IMO3kMrS3LfK0jGU+xPQfgK4jxdefadTW1X7kI3N/vEcfp/Ouwv7lbGwllbAWNS7D1OM4/kPxrzRHeVpJ5jmSQlmPuaD38gwvtKzrPaP5iKvnX9tF23An6Dmus062Mk29u5rH8M2Buppbxx8qny09z3NdnZwBAMCvBzGqpVOVdDtzOsp1bLoWYI8AcVoQJgVXhFW06Vww3PKkTLwaSRs03NNPNb30M7aiE000vekNYSNEMPSoWPWpm6VWkPBrMogtTueQe9Z2rxblerenPmeQe9S6hFmMmqHc7XSrj7XplrPnJkjVj9cc/rVquZ8D3anTjaSSL5sbtsUnnaef55rpq+poT9pTjLueRUjyyaCiiitSAooooA5KzBk+KGoP1EWmxx/TL7q62uR8O5m8f+KZj92NbeFf++MmuurOls35v8zSpuvRBRRRWhmFZXiz/AJFXWf8Arym/9ANatZXiz/kVdZ/68pv/AEA0AHhP/kVdG/68of8A0AVq1leE/wDkVdG/68of/QBWrQAUUUUAFFFFABRRRQAUUUUAFFFFABWB8Qv+RB8S/wDYMuf/AEU1b9YHxC/5EHxL/wBgy5/9FNQBNcWC6r4QNi+MXFmI+exKcH88VS+HF8b3wfYCTIntlNrKp6ho/l5/AA/jW5pP/IKsv+uKf+giuR8Gk6b418UaO3CSSrqEI9n+9j8SBUPSSZcdYtHcU2U4icnoFNOqC/cJYXLn+GNj+lWQcvEcW0K/9MM/+OiuP8TviQn/AGq69iEhBPAWPafx/wD1VwerXH2xIZF6SMWH0zx+ledmT/dpeZ2YOLcnLoje8IxFYMnua7OL/VYrmvD0Pl26D1ros7UryqDtdnTV1ZUnPzmsDWziNq3X+9WDrw+RvpXO9ZGkTuPDa7dA08HvAh/MZrRqjoIxoenD0to//QRV6vq6fwL0PIn8TCkYhVLMcAck0tYPjy//ALN8H6tcAkP5DRpjrub5R+pqm7K4kruxi/C4G8h1vWmH/IRvnZD6xrwv9a7isjwhpo0jwzptjjDRQrv/AN48t+pNa9KCtFIc3eTZ5fd/8lD8T/7lp/6LNXKp3f8AyUPxP/uWn/os1cqiQooooAKytZ/5Cnhr/sLwf+zVq1laz/yFPDX/AGF4P/ZqAPWaKKKACuK8Tz/294k07QLP95HbTJeX7fwoq8qh9znp9Petnxhrf9haQ00SebeTMIbaLu8jdOPbr/8Aro8I6GNF00iZvN1C5bzruY8l5DyefQZOP/r1lP33yL5mkfdXO/kblcVqVyL3VJpVG5ARGnuqk/zbP4Cuh8R3psdMdkJWWQ+WhHYnqfwGTXEwzSSkJZrtCDC/hUV8TCh8W46dGVTY5rx/qv72DS4my5IkmI/MD8+fwFYMiuUSOFS0jkIoHcmtzxloahI9VhUrPuC3C5zu7Z9u351n6Sc6zYj0Yt+Sk1tGSmuZH12WzhRwUpQ3je/qdnplslrZwwJ0jXaeO/c/nmtWJRiqkp/eRyAcSDB+oq3CeBXzGIg4VJRlueJGp7Rc/csIMVOlQoalU1ERMkpppM0ZrRsmwU0mhjgVAz1nItBK2BVZ2+U0+Rs1XnPyGoKINMBN1J6ZzWvex5jx7VlaQD57sfWtyZd0dWthPc5OZ1tpWMpdEHzb0zlSO4xz+VdNo3irNuhvP9IgIylzDzke49fp+VYmqQcnjiuE1CK90W6e406Z47eRtzKOVz7jpivUy7EpfupfIX1OOIejtL8Ge+2N9bX8XmWkySr3x1H1HUfjVmvCdI8U4ukkuM2dwOFuID8v0Yen5/SvT9D8SicxQ6iUR5MeXOh+STPT6E/kf0r2Dz8RhauGdqisdPRRRQc5yfgXE194mugc79Tki/BAAP511lcf8LCZPDUtw3LXF5NKx9SWx/SuwrOj8CZpV+JoKKKK0MwrK8Wf8irrP/XlN/6Aa1ayvFn/ACKus/8AXlN/6AaADwn/AMiro3/XlD/6AK1ayvCf/Iq6N/15Q/8AoArVoAKKKKACiiigAooooAKKKKACiiigArA+IX/Ig+Jf+wZc/wDopq36wPiF/wAiD4l/7Blz/wCimoA1dJ/5BVl/1xT/ANBFchrn/Ev+KOg3n3Y762ks3PqR8w/Uiuv0n/kFWX/XFP8A0EVy3xQQQ6dpWp450/UYJif9ndg/zFRU2uXT+K3c7OqGusV0uYDq+1PzIH9av1jeIpRi2h9WLn6AY/mR+VWQcr4wvBaaHKVOJJhsXHXkf4FvyrmYrfM9tAP+WSKtHii9+369FCP9VCwTA9Sct+n9a0tGj825eYjjPFeRmk/hie9To+ww8L7y1/y/rzOn0qLagHpWhKcDFV7NcKKllbmuCGkDllrIrN96sXXlyh9xWy5xk1k6sPMhY+lc3U2R2+if8gaw/wCveP8A9BFXKpaH/wAgTT/+veP/ANBFXa+sp/Cjx5fEwrifiO/2q78OaOOReagjyr6xx8t/MflXbVw83/Ew+LtuvVNM08v9Hc4/kRRU2t3HT3v2O4oooqyDy+7/AOSh+J/9y0/9FmrlU7v/AJKH4n/3LT/0WauUAFFFFABWVrP/ACFPDX/YXg/9mrVrK1n/AJCnhr/sLwf+zUAes0UUUAcbBGNd+IE88nz2eioIo1PQztyzfUDj6gV2Vcd8LyZdDvbxjlru/mnJ+pA/pXY1lS1jzdzSppLl7HD/ABAuXjdV6IqAL9STn+Qql4UKsgZuppPiaxEvHt/KqHhefEKc14OJm3Xk33PRpRtSSRp+KId+n6mgGf3ZZfqVP9QK850aTdrWnn+9uH/jpr1LUFEySqejw4/X/wCvXkemSeTfWDtx5c6q3sM4NezhJc1JM9DL7ujXprt+jPTUbfphI6xuG/p/WpY3/Wq+mMpeSF+hyD9DToMgFG+8h2mvOzOnaan3PJwkrxcTRhfNWAaoRtg1aV+K8xOx1NEpNIWqMvSFqrmJsKzVBIealJqvKeagtDGNVb6UoEHrVgmqt98yjFMZb0pMIp7nmtoj92KzdNXgVrN9zFaQWjZnJ6mbdQhh0rBu7WMswGP9pD3rp2HBBrI1FFwX4yO9R1KTMTUfD+lxWwV7fbK3LOjEYPsOn6VhRyyeH7uK2unM2kTk7HI/1ZPf8O49K7LWF3ITjoa57VLYX+hXUTDLRjzU9iP/AK2RX1aXKkl0OfD4uVSXsq7vGXfp5rsek+E9Ue6ils7pw1zb9GznenY+57fl610FePeBtTKQ2Ny74ezkEE3/AFzI4J/D/wBBr2GqOOvSdGo6ct0cf8L8x6Dd2rZ3Wl9NAc9sEH+tdhXK+FP9G8SeKLDoBcpdr7+YgJ/Va6qs6WkEuxNT4mwooorQgKyvFn/Iq6z/ANeU3/oBrVrK8Wf8irrP/XlN/wCgGgA8J/8AIq6N/wBeUP8A6AK1ayvCf/Iq6N/15Q/+gCtWgAooooAKKKKACiiigAooooAKKKKACsD4hf8AIg+Jf+wZc/8Aopq36wPiF/yIPiX/ALBlz/6KagDV0n/kFWX/AFxT/wBBFc78VQD4C1XPZUI+u9a6LSf+QVZf9cU/9BFct8UpPN0Wy0tT+81K9htwPbcCT+g/OoqfCy6fxI661JNtCT1KD+Vcl4n1JIZLy6Y/u7dPLXn7xGc/qcflXT6lcCysJJFwCo2oD69BXkPjW8lxZWsYYwSOWkk7FhyF+vf8qq6Tsb4PDvEVo0+jZk6bHJd6ipxlzukcjoCf/wBdegaVaCGJV9BzWJ4WtFisklYDfOS2fYHAH+fWupgGOlfP46o51mn00Pbx1ZVKr5dlp9xcQhVqNjk0ueKYxxWEnpY89LUjl6VQkHmrOo7f4VZnk7CoNNAkuLj0rBI02Om8LTedosAz80WYiPTB4/TFa1ebyazN4fuHlUt9nLZdcZAHqR1/Ec/Wuq0LxRp+rBRHIqSHoNwKk+gPr7HBr6bCVVUpJ9tDzq9GUW5W0N6uH8F/6V428YXx52zx2qn/AHFIP8hXcVxnw1XI8STHrJrFx+hFbS+JGUfhZ2dFFFWQeX3f/JQ/E/8AuWn/AKLNXKp3f/JQ/E/+5af+izVygAooooAKytZ/5Cnhr/sLwf8As1atZWs/8hTw1/2F4P8A2agD1miiigDjvhZ8nh65tj962vZoT9QQf612Ncl4S/0PxN4n048D7St4g9fMXk/mK62sqPwJdjSr8TZ598TY+VbsVB/nXNaBNiNcetd38QbTz9NRwORlT/T+teb6OTGxQ9jXg4yPLWkelh3emju929IT65T8x/jivJ9bt2tdUv4ehEpdfYHkfzr1CBy1iSp+dPmX6iuN8e2gTU7a8QfJOmD/ADH6H9K9DLZ3i4ndl0+TE8r+0rfqa9pdbhbXi/dmRWPse4rXn4cXKD5HwH9j61yPhmYS2c1ix/eREun+6ev6/wA66fSrgFGhl5U8EGuzEUFXpuDPJr05YPESg+n5FtTUyPVTa0D7HyYz9xvX2qTdivmpwlCTjLc601JXRZ3c0jNxUQalZhioGSBvlqvIck07fxUTNzQAjHg1VkPmQqw7VNLJtA+tIoBUqBimM07BgoFaJcYrHtyVUZqw0+BTUrEONyaWTANZU0izsI88swUj05qaWbjJNQafBvuGuNuM8L7+9a4ek6tRRRNSShFtk2oR5tZXPSsfTgHZ0b7rDBrb1yVYrMRdz1rEsiI45pT91FLH8K+nZ5Ub30OU8I3ITVJbR/8AV3UJH/AlBI/QMPxr3Lw7ctd6LaSucvs2MfVlO0/qK8D0IbNa0tumXwfxBH9a9u8EnOjMM8CZ/wAMnP8AWmeznlPlxCl3RQkf7H8UIgeI7/Tiv1dHJ/8AQa66uM8e5s9Z8L6mDgQ3v2dz6LIMH9Aa7OsqejkvM8meyYUUUVqZhWV4s/5FXWf+vKb/ANANatZXiz/kVdZ/68pv/QDQAeE/+RV0b/ryh/8AQBWrWV4T/wCRV0b/AK8of/QBWrQAUUUUAFFFFABRRRQAUUUUAFFFFABWB8Qv+RB8S/8AYMuf/RTVv1gfEL/kQfEv/YMuf/RTUAauk/8AIKsv+uKf+giuR8Tf6V8SvCtq3KwpPcEe+3A/UV12k/8AIKsv+uKf+giuS1Pj4uaNnjOnyge/JqJ7L1RdPd+jLHxEuTDbWUecK8vI/wA/jXO+MI438OiSNRmMI30IbB/Q1t/FGM/2baTAZEcvNY5T+0dAmgzzIjID6EjI/UCvLnNxxmvl+R6OFkoRhPs7/cyDw5Ju0aDHVQD/ADB/Wt+2kzwa4rwjd/6GEfI2MUcf7Lc5/PNdWjFG2k5I5z6j1qMypNSVRbGk1yVqlOXd/czSLgdKikckGoBJmkeT5DXmOVxpEbv1NS6EpZWc9WOTVORugB61d0qQRRYNEd9RvYNWtFmjYlc1yd1o0NmIptNzBdMCQc5Rv9kr6Gutv7rCNtGTnoKzdVi8u2tc8sWr1MsTc5PoYVq06UVyvf8AH1Oi8Ba3/a2lhZCfOi4w3UDpgnuQQR9MVV+GjYi8QwnrHq9wCPTkGud+HtyYvFN9brgRmd+nfduyPzRa3fBH+jeMvGNkcjNzHcgf74JJ/lXrS+JHPiKSpzlFbaP79f1O3oooqzkPL7v/AJKH4n/3LT/0WauVTu/+Sh+J/wDctP8A0WauUAFFFFABWVrP/IU8Nf8AYXg/9mrVrK1n/kKeGv8AsLwf+zUAes0UUUAcffObH4oadIeItQsXt/q6MX/lgV2Fcb8SgbW10rWUBzpt4kj/APXNjhh+PFdirBlDKQQeQRWUNJSiaT1imVNWtftlhLDjLEZX6143dxmw1N1cEAmvcK4Pxto6z3wOAvnDcjdBuHUf1/OuLH4Z1P3kN0b4Wsoe7LYytPu1aPAPUVl+M2Enh22cnmOcDP5j+tVUsdRtpzEkTNg44FUPEF3Nsg0uZNrI/nO2fqAMVzZbGSqN9LHq4aDnXhy7p3+RRSeSxuoL2Hloz8y/3l7iuxikjniivbRt0Mg3D29vrXJMoKbT06VLomonR5mhnBaxlPP+wf7wr2z086y54iPtaa95fijv7W5juITFLyp/MGmMsluD5mXh7OO31rLI8sLcWziSFxlWU5BFaFjqAddrfiDXLicJCutdH3PkqdaVJ2JlfPKkEUB9wyKe1vBKMxkxsf7vT8qhNtcRcRlZR7HB/WvHq4CtT6X9DuhiIS62JMVCzAXBQnkjIpD9pAP+jyfgM1EVlaQObeXeOAdprm9lNbpmqku5JPHviIBwe1OgBVFDckUz/Sc4Fu/4jFSLbXknZI/qf8KuNCpLaLE6kVuyUy7V54qE3W5tsYLMewqZNMLkedKzn0UY/Wr1vY+Wu1ECL+prrpZbUk7z0RhPFRj8OpQhtnkbM4+iD+tbMSJbQGSTG4DgVFI0VquSQWrF1HUTISM8elexRoQorlgjhnUlUd5FTV7nzpSc96patKLbw7cf3pR5a++eP5ZqSJDcTD0rK8VXAlvobKM/u4Bvf/ePQfgP51ozsyzDuviYx6LV/IytOG3WtNX0kFe0+CBjR3/67N/IV4zpGX8S2gAyEDufwQ17Z4PULocbd2kkJ/ByP6Uzv4gd8Ql5EfjfSG1vw3d2kP8Ax8gCSHnHzqcj8+n403wd4hg13TlDPt1GBQl1Aw2sjjg8emc0mveMdE0SUw3t2DcDrFEpdh9ccD8a4LUtd8M69qa3enT3ei6yD+7vGQKjnsHwTwfU/jxxWUk0+eJ5tPC1akPhdu9j16iuQ8L+K5bm+/sjX4FtNVC5jYH93cr/AHkP+f6V19XGamro5ZRcXZhWV4s/5FXWf+vKb/0A1q1leLP+RV1n/rym/wDQDVEh4T/5FXRv+vKH/wBAFatZXhP/AJFXRv8Aryh/9AFatABRRRQAUUUUAFFFFABRRRQAUUUUAFYHxC/5EHxL/wBgy5/9FNW/WB8Qv+RB8S/9gy5/9FNQBq6T/wAgqy/64p/6CK5Hxpmy8aeEdRHCtO9m5/3xgf1rrtJ/5BVl/wBcU/8AQRXPfE20kuPCVxcW/wDx8WLpexn0MZyf0zUT+Eun8Rr+JdPGp6PPb/xY3L9RXmen6g1iDbXAKupBHoeeDXq2l3keo6ba3kJzHcRLIv0IzXLaxaCG/u4wo2SKzrkdAw/xzXJiMGq0lNOzNqNf2acWtDzGO6FrqlxcQ/PbmeQELyGjLHkfzFdlaXaNGiM+6NhmKUen+e1cDZ/8esf0q5ZXUtkx8sCSFjloWOAT6g9jXZKKmuWS0PqsxymVaMalF++l9/8AwTvXLoM43L/eXkf/AFqieZNjYYbscDNY1hq8cjhLefa//PKU7W/DsfwrW/tN4zieI/iM15k8ri3eErHzkq1Si+WrGz+4QujFTvwRzipkklcAQxsfcjAoTWYRz5K/likk1/j91Cq+4FEcrjf3pESxj6IuQ2wjxNdtwvP/AOqsjUbxZrtpn4ggUsfYCorm4ubkM8zeXEOWdzgAVgatfxXEYtbMkwZ3SSEY3kdAPbvXo06caUeWCsPCYWrjqqitur7Gp8Od8niEyN99mV2+p3k/1rq0/wBB+L8g6LqOnA/Vkb/AVhfC2HzdWlmAzsYg/wDAVx/7PW949U2fiXwnqqjCx3htZD7SjH9DTntc3zNp4ycVtt9yR29FFFWeUeX3f/JQ/E/+5af+izVyqd3/AMlD8T/7lp/6LNXKACiiigArK1n/AJCnhr/sLwf+zVq1laz/AMhTw1/2F4P/AGagD1miiigDP1/Tl1bRb2xfH7+JkBPZscH8Dg1n+Ar83/hWxaTIngX7NMp6h0+U59+AfxroK4rTCdA8fX1hIdtnrGbq3J6CYffX6nr+VZS92Sl8jSPvRcfmdrWZ4jtBeaTMMZkjHmp65H+IyPxrTorUzOE0+Zjgbs/uwwPryK4LxooXxTwMZhRv0rvIkWC5eFQQIWliH0DDH6VxXjtf+Klt3x963A/Img9fJHbFr5mVTWUOpDDNOooPuxthe3Wky5hPm2hPzwMePqPQ109lcWupRmSxfbIPvRNwy/hXMZFRPD84kiZo5RyGU4IoPGx+T0sV78NJf1udilzNC2HB4q7DqGcc1yVn4hvbfEeowLdRdPMTAcD+R/Ste21DS7xtsVyI5D/DKNh/Xg0HymIy3EYd+9HTujokvzj71WU1BB1Fc9JZzLzGcio9t0v8JoOE6lb23Jyymnrf2q87c1yoafuDTHafsDQB1T6xCv3EAqjdawzZwcD2rC2TN/CaclrM55BFAElzfMx6kmoYY3uH5HFTtbQ2yebdypGg7ucCs688SQRxmPS4zK/TzGGFH9TQdOHwlbEu1KN/yL2q3sejWWVAe5fiNPU+p9hXIxbyWkmYtLIdzMe5oIlmnae6cyTN1Y0s0gjjLHpSPtcsy6OChd6ye7I9OvI9O1drm4SR0MbINnUE9/yzW/qXxAvn0iHTtHiezAXEk5ILtnk4/u8nr1+lcz5yybWZCEY4DEcGrUcKEDaKY6mXUK9X20tWZAtJJGLuSzE5JJySaHs2QZrpIbF3GQtRXdo6KdwpHVyU9k9SHRNUjmgTStYkYWgOba4H37OTPDKeu31H49a9f8Ea1dXS3Gk60QNXsjhz2mj/AIZB65/w9a8HuECua7XTNSmOi6frsTM97okqwXAzzJaseAfXBJFZVFyP2i+fp/wD53NsEre0j8/8/wBGe21leLP+RV1n/rym/wDQDWjbzR3NvFPCweKVQ6MO4IyDWd4s/wCRV1n/AK8pv/QDWx8wHhP/AJFXRv8Aryh/9AFatZXhP/kVdG/68of/AEAVq0AFFFFABRRRQAUUUUAFFFFABRRRQAVgfEL/AJEHxL/2DLn/ANFNW/WB8Qv+RB8S/wDYMuf/AEU1AGrpP/IKsv8Arin/AKCKmuoI7m2lgmXdFKhRwe4Iwah0n/kFWX/XFP8A0EVaoA4j4YXElra6h4eumzc6TO0ak/xRMSVP8/0rT8SJt1K3f/npGV/75Of/AGasnxfjw34nsPE6KfssoFlqGB0Q/dc/Qj+Qra8UlWtbG6iYOglADA5BVgef0FRDT3exc9fe7nikKN8kCf6wv5Yz2OcZP0rprbR9NkQI7zeaP42Y8/gDj9KxAfL8RzgjAjnnb6D5sfzrp9HjJmjd/ukcGvPxmLnRqKMex9Xj8ROSgoSa0T0dinN4UD/6i4LqezAP/hVcaPrFnxb3LBR0Uscf98nIr0OOzhmUb0VvqKk+wRoPk3AezEU6ePk1eUfxPLljMR8Mpcy80mebn+3142hz67Y/8BTNviBx12ewWL/69elC1UnjefxpkloijksD9a0+vRtezJWJf/PuH/gJ5k+kardPm4zIQcjzZSQPoAOKr6lYXenRK88akOdieWScseg5Ar0G8mitYmeR3xnAAY5J7AVU07TZtZ1ONLi3eKOMearu24L2z1Pzc8fXPappZhGpNQUdzsp5niKKu7cq6JWNn4baV9h0kyvzI2Uz6nOWI/Hj/gNWviPYtfeDtQ8via3X7VGe4aM7uPwBH410cEKQQpFEoWNAFUegpZEWWNkkUMjAqwPcGu+SurHz8qkpTdSW7dyloGoJq2i2N/HjbcQrJx2JHI/A5FX64b4aO+ny6z4cmYltNuSYc94X5X/PvXc0oO6uTNWlY8vu/wDkofif/ctP/RZq5VO7/wCSh+J/9y0/9FmrlUSFFFFABWVrP/IU8Nf9heD/ANmrVrK1n/kKeGv+wvB/7NQB6zRRRQAVzvjnSpNQ0hbmz41HT3F1bEDJLLzt/HGMeuK6KiplFSVmOL5XdGb4c1eHXNGtr+34WVfmTOSjDqp+hrSri9Oi/wCEd8dzWSHZpuro08KdknX74Hpkc/kK7SlTk2td0VNJPTY4rV18jXbr0YiQD6x4P6iuJ+IKbdW09x3V1/Jq7zxehj1W2k7SxbP++W/+yriviMnzabN/tOPzwas7sply4yD/AK2OcJxzUmjWEutTS7JDFbREKzDqx9BVDUZTFakjqeK6uxt1sLCC2AwUUF/dzyT+dcuKxP1dJ2u2fW5niZUoclN2b6j28K2oT/l4J9fM5/lVWTwyEP7q6nQf7ah/5YrTt7yaNgokbB7HmtiCd34lhDj1XisYZjSl8Wh8z9YxtN3jUb/rzOJl0S+T/VSW8q+5Kn/D9az7qwu4wftNg5HqmHH6Zr0h/shPzh0+q5x+VM+x20nMU8f/AH1g/rXVGvTl8MkbwzrGQ/iRTXoeZW07WrYtrme3P90MQPyrRi1vU1xi9RwP78a/0Fd1LpHnDBVZAOzAMKoTeGrdz81lD/wFNv8AKti3m+Fq61qOvy/4Bzq+IdSA5+yN9UP9DQfEWpY4jss/7jf/ABVbL+F7Qk/6Hj6SuP60w+FbP/n2kz/11b/GgX13LH/y6f8AXzMR9f1ZuhtU/wB1D/U1BJqmqSgiS/Kg9o1Vf1AzXSL4aswebQ/jK/8AjT/+Easz0sl/F2/xoKjmOXQ1jR/Bf5nFFI2fdNKZH/vO2TUglhTgMors08M2g5+xR/m3+NWotBt06WVqPrGD/Og6v9YaMVaEH+BwySI/3WBqjqkhIEaAljwAO5rvdY0K3azlkSOGOVVJVkAU5/DrXKeFLT7XfPqFwAYLb7oPRpO35dfypXOqOc06uHlVta3Qua7s07QbLTcDzcDd/vdWP5kj8Kk0Cy84ru6VhahdtqOrvITlEO1f8a6rQpBHtoZOCpzo4VyfxS1fzOwsNIjMIOBWRrunosb4ArYtL1liwDxWTrV2DG4zzSOOg6vtdWeaapHskYCuj+F6rd32paZMMxXtnJGR78EH+dc9rDgytj1roPhNn/hMbXGcbZM/98Gna6selj1zYed+z/A9Q+G14b3wXpjOfniQwH22EqP0ArR8Wf8AIq6z/wBeU3/oBrD+FS48Kbh0e5mYen3sf0rc8Wf8irrP/XlN/wCgGoou8F6Hw9VWmw8J/wDIq6N/15Q/+gCtWsrwn/yKujf9eUP/AKAK1a0ICiiigAooooAKKKKACiiigAooooAKwPiF/wAiD4l/7Blz/wCimrfrA+IX/Ig+Jf8AsGXP/opqANXSf+QVZf8AXFP/AEEVaqrpP/IKsv8Arin/AKCKtUAQX9pBf2U9pdRiSCZCjqe4NcD4aE8Og654bvJDJc6Q+YWPVoeHQ/oR+Qr0WuIvcWvxYs+P3eo6a8Lj+8UYnP5VEtGmXHVOJwmq25Hia8cDCyouP+BD/wCxresyyW8eBypGaj8T2TW6LMozJC22T6DOP5mrtg4a1WQL1Ga8DHT5qzt0PXjUdSEW+iS+43rWf5FINWWnBHvWBa3YYlenOKuCUo2N3FcynKK0JcE2aYudi5xWRq+psmFjUvK/CoOpq3JcJ5XbNcpd6gsWuszniNUGP7oJPP44/SrlOTVrihBX2LNjZ3U04udTwGUkxwg52+59T/L+XW6U5gmtsjDO20j2NRRtbyWizRlSSMg1Bo8xvPEUUfG2BGlPv2/9mq6EWqsbeRNR3g7nY0UUV9KeUcVqqjSviZpV90i1O3eykP8AtrhlJ9zwK7WuL+K6SR+HINSh/wBbpt5FdDHoDg/+hfpXYwSrPBHLGcpIoZT6gjNRHSTRctYpnmV3/wAlD8T/AO5af+izVyqd3/yUPxP/ALlp/wCizVyrICiiigArK1n/AJCnhr/sLwf+zVq1laz/AMhTw1/2F4P/AGagD1miiigAooooA5P4k28p0BNQtB/pOmTpeJ7hT8w+mDn8K6Wwuo76xt7qA5injWRD7EZFPuYY7m3lgmXdFKhRh6gjBrlfhxJJb6deaNctm40q4aAZ6tGfmRvxyfyrL4anr+hpvD0LPjhMW1lOP4Jtp+hB/qBXC/ELD6LaOOqTISfYqR/SvSPFsHn6BdAdYwJR7bSCf0BrzvxJEbrwrMerRgP/AN8t/wDZGtTbBT5MRCXmjh58ST2sbdGdQfzrrbqQtckd81yNmv2jVLFOwYMfw5/pXSwSebekH1rxszfvRR9Nmkr1EX7UbrkZ7V1FlH8tYUcPlkSetdBYMCgxXl7nkyLgt1YcgGmNp8bfwD8qtRmrK4rpp04swlNoyTpsIOdmD7Uv2Ej7k0q59HNajAVGw54rTk5Nhc19zPWzkH/LxKfqc0jWcp/5epce1aCoWqTy8CqTm+r+8l8vYyTYyf8APxIfxqKW1kH/AC3l/Bq1ZDtqnPIKznOS6suKT6GeLc/xSyn6uaint4FGZCT9Tmpp7lY1ZmPQVzkJl12WSR3eOwRioCnBmI689hXK5Se7Nkia9jiuHWGBlUsevXFc/wCJbqDSdPTStPyPlwz9zzyfqa6q18NwJfWsluzW6s4WTDkgqTz16H3rgPHRH/CU30aKEihkMSKOgVTj+mfxr2MrS5ZM6MNR9vWUZfCtbd30KWnKBzXQWVx5ZGa56zYDFaqtxxXqH1cIqUbM6RdUCpgGsvUtQ3qcGs9pMDrVG6nwDSsZrDwp6lK8ctJXZ+ASNN0/W9ZbgWloUQ/9NH4X+X61w6gyyivSLfTHXQvD2hMMSaxd/apx3EKAHH5c1NSXLFtHmZnVUaDX82n6v8D0PwPZHT/COlW7DawgDsPQt8x/U1P4s/5FXWf+vKb/ANANaoAAAAwBWV4s/wCRV1n/AK8pv/QDVRXKkj4uTu7h4T/5FXRv+vKH/wBAFatZXhP/AJFXRv8Aryh/9AFatMQUUUUAFFFFABRRRQAUUUUAFFFFABWB8Qv+RB8S/wDYMuf/AEU1b9YHxC/5EHxL/wBgy5/9FNQBq6T/AMgqy/64p/6CKtVV0n/kFWX/AFxT/wBBFWqACuI8W/uviH4Om9WuIyfqg/xrt64j4jfuNV8J3p+7FqSxk/74/wDrVFT4S6fxEfiEGDUr2C5X91cfOjHoeOaq6ZCP7PVfQcVs/E21efww8sRKvBIr5HoeP6iua8J3pu7FNx+cfK31r5/G0fZVXbrqelQnz00wmgkjmLp+IqdGdl5JBrUa23jIqF7U9utcprcpHzdv3uK4TxZFdSeKdNbT8m5dkhZezgt90+3NegTR+VGxNZfhizF540hldQRbRvOc+w2j9WB/CtKMOeaj3By5U5EujGQJJArNsjkKAe1dF4OttmtX0h6rEq/99En/ANlrI8OoGmuSenmk10vhQZu9Tf8A2kX8t3+NdGBjetH5/kY4h+4zo6KKK+hPLMvxTZDUfDep2hGTLbuoHvg4/XFZ/wAOL37f4I0iYnLLCIj9UJX+ldIRkYPSuJ+FCmDR9UsT/wAuepTwgewwf6moek0WtYMxbv8A5KH4n/3LT/0WauVTu/8Akofif/ctP/RZq5VkBRRRQAVlaz/yFPDX/YXg/wDZq1aytZ/5Cnhr/sLwf+zUAes0UUUAFFFFABXG6m50b4iafd8La6tD9llPbzV5Qn3IIUfjXZVzPxF0977wrcvBkXNoRdwkdQycnH4ZrOqvduumpdN+9Z9TobyEXNpPA33ZUZD+IxXm0A8/RrmCTgkMpH4H+uK9C0a9XUtJs71MAXEKy4HbIyR+Fcbcwi31XU4D/f3gex+YfzAq07q5KvFnluiAjUCxGDGhH0PSugsV23hJ781nxWxt73UCR/y32j+f9RW3BHuCuOteDj5XrPyPpMXVVWfMuyNZmAgrQ0x8qKzokLx4qxYbomIPSuE5GdAjYqwkvHNZ8cmRUgkq4VHEzcbl1mz3pgfBqvvpMkmtPbXJ5C8kgpHnGKpknFV5HOetN12tAVO5NcXA55rB1TVY7ZSWYZpdXvPs0XHLsQqqO5PQVkJ4ebUT5mpXEjc5McR2qPbPU/hisZSvqzWMUip9pudbnNtakpBn9/P2Qeg9WNdRaQJb2ypGuyJF2ovoKW1tIbSFIYY1ihToiirCxPO6gAiMfrUblNl+JA9rzwcV4/44tnTXbqVskyOXz655/nmvYnxHDjNYuq+Gh4g0SSe3A+2xSMEyfvrgfL+ecV6eXyaq8vkb4LEQo1L1HZPT0PHLeTaRV9brA61FfabNbTvG8bK6HDKRgg+9VxDJ3Br2z6SLlEsyXJPeqjO0rYHNTR2jMeRXT+F/CV7q8qmCPZADhp3Hyr9PU+woJqTUI89R2QeAvDjavrESSITbR4kmbtt9Px6fnXpSRpc/E9m/hsdNCquOFZ3PP/fNb2haRbaLYLa2gOOruert6msLRv8AkpHiLP8Az72+Ppis6m8V5nyGPxv1uo3H4UtP8/mddWV4s/5FXWf+vKb/ANANatZXiz/kVdZ/68pv/QDWh5QeE/8AkVdG/wCvKH/0AVq1leE/+RV0b/ryh/8AQBWrQAUUUUAFFFFABRRRQAUUUUAFFFFABWB8Qv8AkQfEv/YMuf8A0U1b9YHxC/5EHxL/ANgy5/8ARTUAauk/8gqy/wCuKf8AoIq1VXSf+QVZf9cU/wDQRVqgArifi8NnhNLkDm1u4Zvphsf1rtq5T4pw+d4C1df7sav/AN8up/pUVPhZdP40busQi80W7iIz5kLYHvjj9a8l8Hv5F7PD0Gc4r1vRpPtOjWMrc+Zbox/FRXkenL5PiWde2T/OvKzNfDI7MG9JI9DtBuQ1FMuHqWxb5KbP9+vOl/DRuviMrVB+6NM8CxD7ZrVx3SFUH47if5Cnaqf3Rp3gTI0nXZj3Yj8kz/WtcEv3l/X8hVv4ZX8NjEcrf7RNdF4L+a3v5PW5K/kq/wCNYWgDFm7eu41v+CBjSp2/vXDn9AP6Vvl6/er0ZniX7rOgooor3TzgrjvBH7nxH4utgMBb5Zv++0z/AErsa4/w0dvxB8Xp03fZWx/2zNRLdFx2f9dTn7v/AJKH4n/3LT/0WauVTu/+Sh+J/wDctP8A0WauVZAUUUUAFZWs/wDIU8Nf9heD/wBmrVrK1n/kKeGv+wvB/wCzUAes0UUUAFFFFABSOqupVwCrDBB7ilooA5L4byeVpV7pbMS2mXstsM9SobIP6n8qTxTEYdXjmX/ltFtPuVP/ANdRTPDf+jfEDxTbLwkognA9yvJ/M1r+J4Q8NrJjJSXBPoMZP6qKypP3Ldv0NKnxX7nmfia2FpmROssvmH/vkD+lLo0oddprd1a2W9s2GPlHA9q5PSRJDfGFuqnFfO15qpUlJHrU7qCT3Ovt1AFSMyqaZEDsHrVa7JHIrAZpRSjFSbjjNY9pcbuCea04ZQVwapRuS9CZZSKsRPuNUC+DT0mxSWjBq6NQgbapXBUZxSG5+XFU5pCxNaylFrQiMWc7f3H2nXFT/lnap5h92PC/1NdNozrLEMda4I3KJ4j1O1Zwss8aPGCfvbc5A/OtfQdWa2mWObjnjNZ2NmtNDvvsiEZI5qJiIjxwKkgvFlhBB7VSu5huPPFa1OVJcphFNvUq6tehIiAeTXUeGIfJ0K0B+86+Yf8AgXP9a86vm+130NupP7yRY/zOK9XRFjRUQYVQAB6Cu/LIe9KbMcW7RUTM1nQdO1hf9NtwZAMCRflcfj/jXOyfDnTSfkurpR77T/Su3pk0iQxPLK6pGilmZjgKBySTXsGdHH4iguWnNpHA6bpnhOy8YDw27Pda0LL7f5cxyvlb9mcDAznsR0rv440ijWOJFRFGFVRgAfSvgX/ha0//AAv7/hOdzfY/tuzZg/8AHn/q9uPXy+f97mvvmGRJoklidXjdQyspyGB5BBoMq2Iq13erJsfXHzN9i+KVuSuI9Q08xg+siMW/9BxXYVxvxF/0OXQNXHH2O+VXPpG/DfyFZVdI37E09XbudlWV4s/5FXWf+vKb/wBANatZXiz/AJFXWf8Arym/9ANamYeE/wDkVdG/68of/QBWrWV4T/5FXRv+vKH/ANAFatABRRRQAUUUUAFFFFABRRRQAUUUUAFYHxC/5EHxL/2DLn/0U1b9YHxC/wCRB8S/9gy5/wDRTUAauk/8gqy/64p/6CKtVV0n/kFWX/XFP/QRVqgArE8cRed4P1pP+nSQ/kpP9K26o67H52iahEf47eRfzU0paocdGir4NfzPCOiNnObKHP8A3wK85lh2eJJmH/PRh+td38OZPM8DaK2c4twv5ZH9K5O9jxrs+OvnMP1rysy+CDO7C6TkjprH/Vj6Us/3zRYjCD6UT9a8t/wzf7Rj6r/qzUvgw/8AFJ6ye/nSL/5DX/Go9WH7kmpPCHy+DtXPrPJ/6AgrfB/E35MVb4V6oboh/wCJVu/2DXQ+C1xoETf3pJD/AOPEf0rntMG3Rv8AgBrpvCa7PD9oPUMfzYmunLtany/UxxXw/M16KKK9o4ArjvDQ3fEHxc/90Wq/+Q67GuO8E/vfE3i+467r1Iv++Ex/Wolui47P+upgXf8AyUPxP/uWn/os1cqnd/8AJQ/E/wDuWn/os1cqyAooooAKytZ/5Cnhr/sLwf8As1atZWs/8hTw1/2F4P8A2agD1miiigAooooAKKKKAOOsf3XxU1JG487TkkHvhgK6LXQTpcxXqBmuc8WZ0vxdoGtD/USMdPuD6B/uE+wOT+FdfNGssTxv91wVNc/K5RnBb6/ibN2cZf1ocDpcqy2rqTyCRWJeWwj1NZAME1f1C2uNE1FklU+U5yrdiKrzSC4uYwvrya+bcXB2Z6kWnqjYiTMYPtVO6ThhWjBxGBUVxHmpA5/5opM9qvRTZHWpJbdWBquICh4pjLYkJphlIaljHY08he9ADTccUzzSTUnlqRUcihKAPNviVbbp0uIiUmTlWU4INWPCOovrmlSm4x9utCFdh/GOzVJ4v/fuydc/pWh4A0IWvhy91I5DTS+QPQhRkn8z+laJNrToU2ktTpNHu5Hsvvcrwa0JS0ka4PJFY2gKfKlHua6G3gzEM+lQSzJ0e2L+KNOjPP73f/3yC39K9TrgvDcO7xWhP/LOJ3/kP613te5lqtSb8zzsW7zS8gryX9pjxHc6R8OpNI0iOafWtff+z7aCBC8jIRmUhRyfl+X/AIGK9aqJraB7qO5aGI3EasiSlRvVSQSAeoBwMj2Fegcp+ew+DXjM65/Yv9nxf2x/ZX9sfY/OXzPJ83ytvpvzztz09+K+tP2Z/Edzq/w6j0jV45oNa0B/7PuYJ0KSKgGYiVPI+X5f+AGpf+bp/wDuTP8A2+r1BbaBLqS5WGIXEiqjyhRvZQSQCepAycD3NAEtc/4/s/t/g3VYQMssJlH1T5v6V0FMmjWaGSKQZR1KkexGKmUeZNDi+VplLw9dG+0HTbpjlpreN2+pUE/rUXiz/kVdZ/68pv8A0A1l/DSRj4Tgt5DmWzlktn+qucfoRWp4s/5FXWf+vKb/ANANKm+aKY5q0mg8J/8AIq6N/wBeUP8A6AK1ayvCf/Iq6N/15Q/+gCtWrJCiiigAooooAKKKKACiiigAooooAKpa3p8er6Nf6bM7pFeW8lu7JjcodSpIz35q7RQByUPhnXYYY4o/GmpBEUKo+x2nQD/rlT/+Ed1//oddS/8AAK0/+NV1VFAHK/8ACO6//wBDrqX/AIBWn/xqmTeG9ekidG8Z6kQykEfYrTn/AMhV1tFAHlvwz0TW7jwXYND4u1CBAZFEa2lswXEjDqYya1ZPAWoSTtM3i7U/MZixP2S16n/tnVz4V/J4Ylh/543k8f0w5/xrsayUIziuZXNJScZuzOKTwdq6DC+MtTA/69LX/wCN0N4N1ZuvjLU//AS1/wDjddrRS+r0tuVfcL2k+5wc3gTUpl2yeMNUI/69bX/43S2fgXUrSwms4PGGqLBKxZl+y2pyTjv5fsK7uinGhTjtFA6k3uzhIvA2pxweUnjDVAmMY+yWv/xurlr4W1u1t0hh8Z6ksaDAH2O1P/tKuvopwpQhrFWE5yluzlf+Ed1//oddS/8AAK0/+NUf8I7r/wD0Oupf+AVp/wDGq6qitCTlf+Ee1/8A6HXUv/AK0/8AjVch8NtF1u8sNWvYvFmoQfaNRmb5bS2bf0G45jP6cV6Zrl2LDRr67Y4EEDyfkpNYXwutDaeBdLVh88qGY++5iR+hFQ/iSLXwNmTN4Yn0i7u9SutUudTuL0oJZZo4027FwoARQOme1R1315At1bSQv0cYz6Hsa4SaNoZXjkGHUkEVZAyiiigArK1n/kKeGv8AsLwf+zVq1laz/wAhTw1/2F4P/ZqAPWaKKKACiiigAooooAzPE2lrrOg3tiwBaWMhCf4XHKn8DiqfgXVX1jwzaXFwT9pQGGbPXepwSfc8H8a3643wKPs2veK7AcLHei4UenmAn+grKWk0++hotYNdix8SLdpfDpljyHhkDZHYHj/CvLNC1N/tvlzE5zwTXuGt2v2zSbu3AyXjYL9ccfrXz7cgw3KuvBBzXk5jC1RS7o7sHK8HE9QtJNyjmrTjIrF0O4EsCHPat1RkV5h0MptGaZ5frWoIgVqNocdqrldri5jNaL2phU5rRaOmGGpuMpKpFVrxtqn6Voum0VkX5J3AU0NHIawikSSHqM16NLYjTPAOmWwXa3lh3H+0w3H9TXCm3+2axZWh6T3EcZ+hYA16f49bbpsQHcmu2jH9zUn6L8TGrL34ROP8OAlGHq1dSiBYSfaub8Nrhcnpmunl4tyfauWKumy5vUq+FOfFEx7C1Yf+PrXbVxPgoF9cvX7LCB+bf/Wrtq93L1agjz8V/ECiiiu05zyr/m6f/uTP/b6vVa8q/wCbp/8AuTP/AG+r1WgAooooA4/wIxh1jxVZMf8AV6i04HoJBn+lbfiz/kVdZ/68pv8A0A1h6P8A6P8AE3XohwLm1hnx/ugL/WtzxZ/yKus/9eU3/oBrKl8NvN/maVN7+geE/wDkVdG/68of/QBWrWV4T/5FXRv+vKH/ANAFatamYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHG/DI4s9ci/55atcr+oP9a7KuL+G5xdeK4/7usTt+eP8ACu0qKfwoup8TCiiirICiiigAooooAKKKKAOP+K900Pgy4giz517JHaoB3LNz+gNdRp1qtlp9tax/cgiWNfoAB/SuT8W41Lxn4Z0kfMkUj6hMPQIMJ+pIrtKiOsmy5aRSCua8U2e2RLpBw3yv9ex/z6V0tQ3kC3VtJC/RxjPoexqyDgaKfNG0MrxyDDqSCKZQAVlaz/yFPDX/AGF4P/Zq1aytZ/5Cnhr/ALC8H/s1AHrNFFFABRRRQAUUUUAFcdov7r4l+Ik7TW8Ev5KFrsa4+BTH8WLkdpNJD/lKBWVTePqaQ2fodhXhfjCwFrqt1EBhVkbb9M8V7pXl3xOtfL1TzQOJEDH+X9K48yjempdmdGDlabRk+E5j5YQ9q7SA5UV574bk2XJWu+s2yorwpHfI0YhkU+ROKLbkVLIOK6or3Tnb1M9xg0mKllHNRkVyS3NUVLnoaxLoZLVuXX3TWFdnG400Uin4Sg+0+NrEHlYi8h/BTj9cV2nxDfbZW49S39K5z4bRiTxVcyEf6u2bH1LL/wDXroPiHzDbj6mvTirYOT7v9Uc0nfEJGF4dH7oZrfuzttW+lYmgcxVr6mdto30rij8LNpfEHgEbrzVHP/TMD/x6uyrkPh4Mxai/rKo/If8A165f9p3VdQ0b4RaheaPfXdhdrPAqz2szRSAGQAgMpB5Fe7gVahH+up5+I/iM9Xor510PxldeEfGfiqPWtT1XR9OXRIb+zstclk1Ng2VVpVIlb5SxI2CUEk9scZ/iv4k6z4i8L+OvDmuWEcSr4fGp21wLQ2rvGXRfmi86bGd4IO4HA5ArrMD3D/hEf+Lp/wDCZfbv+YL/AGR9j8r/AKb+b5m/d+G3b757V1VfN/w9+MN3D8O9TvrW2sn0fwpotlb/AGZwwu7m5MapvzuwsO7j7pJxn2rVb4teMLXRdZvbnRI5reHRhqVrqH9kXlrbLNlcwP5pG/hsh1IBxwPQA97orzDwtpesfEPQfD+seP00xbeOW21jT7TS3fY5MOV+0CQHJBfIVTgdy2Ocvwh8UNU1Lx9JoXib7N4euGu5IbXTLjS52luEVcqVuvMEeT97/V4IxgnNAHZSfuvizGR/y20kg/US/wD1q3PFn/Iq6z/15Tf+gGsO+4+Kmmn105x/48a3PFn/ACKus/8AXlN/6Aayp/a9TSp09A8J/wDIq6N/15Q/+gCtWsrwn/yKujf9eUP/AKAK1a1MwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOJ8AfL4i8Yx+mobvzBrtq4jwR8vjLxnH0/wBJibH1U129RT+Eup8X3fkFFFFWQFFFFABRRRQAUUVkeLtUGjeGtRvsgPFC3l+7nhf1IpN2VxpXdjnPB5Or+N/EWt5zBCV063PYheXx+IB/Gu6rnvAOkHRfCljayD9+U82Ynrvbk5+mcfhXQ1MFZalTd5aBRRRVkHNeKbPbIl0g4b5X+vY/59KwK768gW6tpIX6OMZ9D2NcLPE0MzxyDDocEUAR1laz/wAhTw1/2F4P/Zq1aytZ/wCQp4a/7C8H/s1AHrNFFFABRRRQAUUUUAFcnP8AJ8UbZv8AnppTJ+Uua6yuU1T5PiPobf8APS0nT8sGs6my9UXT6+jOrrhvibDughfHVWH5f/rrua5H4irmwgPpuH8q58cr0JfL8zTDO1RHmGiHbfD6V6Fp5ygrzvTflvx7V6BprZQV89I9WRt2pqeXpVa2NWG5U11U3eFjml8RUk61Gakk61Ea5Jbmq2Kt0flNc/qTbY2Nb92flrnNWP7thQi0afwoXfqWqy/3URfzJ/wrW+IB/wBSv+zn9ao/CWPaurP/AHnjH5Bv8as/EF8XMK/9Mx/M16stMEv66nItcS/66FPQlxAtX9ZOLU/SquiriFKsa4cWx+leevgN38Rc+HQ/4lN05/iuW/8AQVrS8W+GdI8XaJLpHiG0+2afIyu8XmPHkqcjlCD196qfD9caAT/emc/yH9K6SvocKrUY+h5tf+Izjo/hp4TVNQWbS2vGv7cWlxLfXc11I8IIIQPK7MqggEBSOQD1FV4fhP4Ni+2/8SueRryy/s6dptQuZWe3ypEeWkJAGxcYwQBgccVR+PnijVvCfgMXugzraXc97Bam8aNZBao7fNIVYFT028/3qxviPrfiHwPotlrFr4pk1ix0/UbY6tFLbW/mm0k4bcY0GOSpUhVODyWroMjsofhv4Shuzcpo8fmHTl0lw0sjJJaqoVY3QttfAAG5gW4HPAqJPhl4UWwnsmsbuWzltms/Im1G5lSOFiCUjDSERj5V+5joK8zt/E/xM1rwHB4m0Vbi4tNR1aWYQW0NuLq204NiNYhIpVmbByzBjgggYzXPnWV8afEf4S6np/iDXokuF1KAXF5DaJcRSIh3YCxeWSchPukYAwA2SQD6V0qwttK0yz06wj8qztIUt4Y9xbYiKFUZJJOAByTmsK08C6Db61a6s0F7d6haFjbS3+o3N35BYYYossjBSR3AFdPRQBx9/wD8lT0z20+T/wBCNbfiz/kVdZ/68pv/AEA1h3nPxWsB/d0xz/4+a3PFn/Iq6z/15Tf+gGsqe8vU0qdPQPCf/Iq6N/15Q/8AoArVrK8J/wDIq6N/15Q/+gCtWtTMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDifCI2/EHxko6brZvzQ121cT4Y4+JPjADoVtT/AOQ67aop7ff+ZdTf5L8goooqyAooooAKKKKACuG8aM2seLNB8PR/NCr/AG+7HUbEPyg/U5/Su5rh/AyHUfE/ifW5OQ1z9igP+xHwcexOKieto9y4aXl2O4oooqyAooooAK5vxTZ7XS6QcN8r/Xsa6SoruBbm2khf7rjH096AOArK1n/kKeGv+wvB/wCzVsTxNDM8UgwyEg1j6z/yFPDX/YXg/wDZqAPWaKKKACiiigAooooAK5TxD8nj3wm394XaH/v2DXV1yniv5fFfhOT0uJk/OOs6vw/NfmXT3+T/ACOrrmPiAudKjPo5H6V09c746GdGU/8ATUfyNZYxXoyLofxEeTWybbsHHeu30s/ItcokX74Gus0ofKK+bZ6zNy3qyehqtD2qx2rop/Cc8tyrJ1NRN0qWTrUTdK5pbmi2KN2eK53V/uGuhu653V/uGhFo6f4VL/xLb9/W42/ko/xqLx8c6jGPRFH86s/CkY0C7J73b/8AoKVR8fE/2mMeij9K9atpg4/13OOGuIZZ0ofuUpviFsWp+lSaUP8AR46r+JD+4IrzvsHR9o6DwKu3wzak9WZ2/wDHzW/WP4QXb4bsfdCfzJNbFfSUFalFeSPLqu836lbUtPs9UspbPU7S3vLOXHmQXESyRvggjKsCDggH8K53XfAWh6n4Nv8AwxaWy6Lpl6Aso0qKKA43AnA2FecYPHQmurorUgwZ/B3h270nTtN1DRNNv7PTolhtY7y2ScRKFC/LuBxwozj0qW98K+Hr7T7WwvtB0m5sbU5t7eazjeOH/cUjC/hWzRQAUUUUAcdL83xahH9zSCf/ACKa3PFn/Iq6z/15Tf8AoBrDg+f4s3B/uaSB+coNbniz/kVdZ/68pv8A0A1lS6+ppU6egeE/+RV0b/ryh/8AQBWrWV4T/wCRV0b/AK8of/QBWrWpmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxPhn/kpfi/8A3LX/ANF121cT4Z/5KX4v/wBy1/8ARddtUQ2+/wDMupv8l+QUUUVZAUUUUAFFFFAFHXL0abot9et/y7wPIPqASKx/hvZfYvBWmBuZJo/tDn1Lnd/UVT+LU7R+DZreI4lvJo7Zcd9zZI/IGussrdLWzgt4xhIo1jUewGBUbz9C9oepNRRRVkBRRRQAUUUUAc34ps9rpdIOG+V/r2NcVrP/ACFPDX/YXg/9mr1S7gW5tpIX+64x9PevLvEETQ614djkGGXWIAf/AB6gD1aiiigAooooAKKKKACuU8acaz4WbuNQ2/mprq65Txv/AMhPwv6/2kn/AKCazq/D935l0/iOrrC8aLu0U/8AXQfyNbtYvi8Z0ST2ZajFfwZeg6P8RHmxj2sDXQaX9wViOMkVvaYMIK+ZZ67NmDqKnbpUMAqduldEPhMJblaTrULdKmkqE1zT3NIlK7HBrnNWPymumuvuGuY1j/VtQi0dj8L1x4ZY/wB64c/yH9Ky/HWDquPdf5Ctj4aDHhaP/rq/86xvGfzawfqP5CvWxWmFgvT8mcdL+PIvaZ/x7pVHxI37pvYVoaaMQLWZ4l/1b/SvN+ydK+I7Xw2mzQNOH/TBD+YzWjVXSl2aXZp/dhQf+OirVfT01aKR5MneTCiiirJCiiigAooooA47Tfn+KWsN/csYk/Mg1ueLP+RV1n/rym/9ANYegfP8SPFD9kitk/NM/wBK3PFn/Iq6z/15Tf8AoBrKls/V/maVN16L8g8J/wDIq6N/15Q/+gCtWsrwn/yKujf9eUP/AKAK1a1MwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOJ8Kf8lE8ZfW1/wDQDXbVxHgznx14zYdPNgH4hTXb1FPb7/zLqb/d+QUUUVZAUUUUAFFFFAHD+Pf9M8UeEdNHIe8a5Ye0Yz/jXcVxN2puvi7ZL1Sy0xpfozOV/lXbVEN2y57JBRRRVkBRRRQAUUUUAFcF8SoorXUfDWoSyJFCNWtxK7sFVfvYJJrvagvLS2vYTDeW8NxETnZKgdc/Q0AUf+Ek0P8A6DOm/wDgUn+NH/CSaH/0GdN/8Ck/xo/4RvQ/+gNpv/gKn+FH/CN6H/0BtN/8BU/woAP+Ek0P/oM6b/4FJ/jR/wAJJof/AEGdN/8AApP8aP8AhG9D/wCgNpv/AICp/hR/wjeh/wDQG03/AMBU/wAKAD/hJND/AOgzpv8A4FJ/jR/wkmh/9BnTf/ApP8aP+Eb0P/oDab/4Cp/hR/wjeh/9AbTf/AVP8KAD/hJND/6DOm/+BSf41zHi/W9KuNU8NtDqdjIkV+HkKXCEINp5PPArp/8AhG9D/wCgNpv/AICp/hR/wjeh/wDQG03/AMBU/wAKmUeZWHF8ruH/AAkmh/8AQZ03/wACk/xrN8Qa5o1zpcsaavpzMSOBcoe/1rS/4RvQ/wDoDab/AOAqf4Uf8I3of/QG03/wFT/CicFOLi+oRfK0zztrrTc8alYnH/Twn+NadnqmlRqAdUsB/wBvCf412P8Awjeh/wDQG03/AMBU/wAKP+Eb0P8A6A2m/wDgKn+Fee8th3On63LsYEWt6QB/yFtP/wDAlP8AGntruj/9BbT/APwJT/Gtz/hG9D/6A2m/+Aqf4Uf8I3of/QG03/wFT/CqWXxStcn6w+xzcmuaQT/yFdP/APAlP8ajOt6Sf+YrYf8AgSn+NdR/wjeh/wDQG03/AMBU/wAKP+Eb0P8A6A2m/wDgKn+FZvK4v7RSxTXQ4651nSipxqlh/wCBCf41zeralp7qQmoWZ+k6/wCNeq/8I3of/QG03/wFT/Cj/hG9D/6A2m/+Aqf4ULK4r7RSxj7HOeAdb0i18ORRz6tp6P5jna1ygPX61j+JtX0yfVmaPUrFk3dRcIR/Ou7/AOEb0P8A6A2m/wDgKn+FH/COaH/0BtN/8BU/wrpq4RVKcabexlGu4zc7bnK2ms6QkSg6tp4P/Xyn+NZ2u6rpcyvs1OwbjtcIf613f/COaH/0BtN/8BU/wo/4RvQ/+gNpv/gKn+FYf2bG1uYv6073sMh8Q6GkMaf2zpvyqB/x9J/jT/8AhJND/wCgzpv/AIFJ/jR/wjeh/wDQG03/AMBU/wAKP+Eb0P8A6A2m/wDgKn+Fekcof8JJof8A0GdN/wDApP8AGj/hJND/AOgzpv8A4FJ/jR/wjeh/9AbTf/AVP8KP+Eb0P/oDab/4Cp/hQAf8JJof/QZ03/wKT/Gj/hJND/6DOm/+BSf40f8ACN6H/wBAbTf/AAFT/Cj/AIRvQ/8AoDab/wCAqf4UAH/CSaH/ANBnTf8AwKT/ABo/4STQ/wDoM6b/AOBSf40f8I3of/QG03/wFT/Cj/hG9D/6A2m/+Aqf4UAcl4U1zSV8XeK7iXVLBElmhVGa4QBgqkcc81s+KfEOiv4Y1dU1fTmZrOYAC5QknYeOtaY8OaGc/wDEm03/AMBU/wAKX/hG9D/6A2m/+Aqf4VMI8qsVKXM7h4T/AORV0b/ryh/9AFatIiqiqqKFVRgADAApaokKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDiPAo3eLfGb/wDT2i/kprt64n4e/NrfjCT11Nl/Ku2qKfwl1PiCiiirICiiigAooooA47w//pPxH8TXHUW8VvbKfqpYj867GuM+HbfaLzxTeZz5mqyRg+oQAD+ddnUQ2Lqb2CiiirICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDi/hsMv4nl/v6zcc+wIrtK474XgNo+pTD/ltqVw+fX5sf0rsain8KLqfEwoooqyAooooAKR2CqWPQDNKDmqHiCf7NoeozZx5dvI/5KTSbsNK7scx8IQX8JNdN1uruab82x/Su2rmPhlB9n8C6OmMZiL/APfTE/1rp6mn8KKqfEwoooqyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApsriON3booJP4U6s3xLcfZfDuqT/wDPO1kYfgppN2Q0ruxhfChCPA9lIesryyH3zI1dfXP/AA+g+z+CdFT1tUf/AL6G7+tdBShpFDm7yYUUUVRIUUUUAJjnNYHj2TyvBmsv/wBOzr+Yx/Wugrlvig+zwJqpHdFH5uKiekWXDWSNXwtEYPDOkxEYKWkSke+wVqVX05PL0+1Q9ViUfoKsVS0RL1YUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXI/FW7Nt4IvkTmW5KW8Y9SzDI/LNddXB6rnxP4+srGE79N0U/ablh0M5+4n1GM/nUVNrdy6a96/Y7LSbYWWl2dqOkEKRf8AfKgf0q1RRVkBRRRQAUUUUAFcj8WP+RC1P/tn/wCjFrrq5f4np5ngTVh6Rq35OpqKnwsun8aOlg/1Ef8Auj+VPqGyYPZwMpyDGpH5VNVogKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKzNZ17S9Fi36nfQW/GQrNlj9FHJrk31zX/ABW3keG7WTTNMY4fUrpcOy/9M0/r/Kpc0tOpag3r0NHxf4kmhuE0Pw8q3Gu3HGBytsveR/THp/k6fhHQIfDuki1jkaad2Ms87felkPVjR4Z8NWHh6BxaK0lzLzNcyndJKfUn+lbdKMXfmkEpK3LEKKKKsgKKKKACiisjxert4X1Tyv8AWLbu6/VRkfypN2VxpXdjXrD8cw/aPB2sR/8ATq7fkM/0rXtJ0urWG4iOY5UEin2IyKbfQC6sri3PSWNoz+IxQ1dWCLs7lTwzP9p8OaVPnJktYmP1KCtKuV+F9w0/gnT1k/1sG+Bh6bGIA/LFdVSg7xTHNWk0FFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFc14i8ZaXosgtgz3uoscJZ2o3yE++On41lGw8UeKU3alcnQNOb/l1tjuncf7T/wAP0H4ioc1stS1B7vRGtrvjPSNIuPshle71A8LaWq+ZIT6HHAP1rIeHxh4kOJnTw7pzfwxnzLlh6Z6L+hro/D/hvStAi26baJG5GHmb5pH+rHn+lbFHK5fEx8yj8KOa0LwVomjv50dt9qu85NzdHzJCfXJ4H4V0tFFUklsQ23qwooopiCiiigAooooAKbKqPE6SAFGUhgemO9OrlfEupTajO/h/RG3Xky7bq4XlbSM9ST/fIyAvXvSk7IcVdlzwFKZvBukMc8W6oM9wvyg/kBW9VfT7SKwsLa0twRDBGsSA+ijA/lViiKsrBJ3bZx/gsrp2veI9Gf5WF2b6EHvHKB09gRj8a7CuH8csdE8Q6L4jXPkq32K7x08pjkE/Q5P5V3AORkdKmGl49i562l3CiiirMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoJwMnpXM6l4riN1Jp+gQNq2qJ96OJsRRe7ydB9OtZp8HX+uHzfFurzyg8/YrJjFAnt6t9TzUOX8upah1lodJf+INH0/P23U7OEj+Fplz+Wc1h3HxG8NxkrDeS3L/3YIHb9cYrR0/wb4e08D7NpFpkdGkTzD+bZrcihihXbFGka+iqBR77D3EcUfHdzefLofhrVrtjwHlj8lP8Avo5pq6T4t19s63qMekWLdbSw5kI9DJ2/Cu6oo5G92PnS+FGPoHhrSdBU/wBmWaRSMMNKfmkb6sea2KKKpJLRENt6sKKKKYgooooAKKKKACiiigAoopDweKAFpkUUcRcxRom9izbQBuJ7n1NPooAKKaCT1p1AGT4r0xdY8OahYsoLSwts9nHKn8wKg8C351LwhpVyzFnMCo5PUsvyn9Qa3a474YkR6dq9mPu2mp3EKj0GQf61D0mi1rBnY0UUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHPeJ9ZurO5s9N0iCOfVLzcUEpISNFHzO2Pw471jpaxajosOo+JPEF2YJEHm20Ti3jDfxRkJ8zEHIxnNWvFMh0rxXoWsS4FkQ9jcOeke/BRj6DcME1dvp/DmnaoZ5YLY6mf3h8i382bnvhQSM+tZPVu5qtErC+B7BdP0Z4orU2ts07vbxuuJBGT8u/vnr15xjPNa97qNlY4+23lvb56ebKqfzNcw+p6j4i1YabaJd6PZpGJ5ZpV2TzJkjCD+EZHJPPTirdxH4c8OMmbaH7bIcoixma5lPt1Y/U8U07LTYTV3rubtlfWl/Gz2VzDcIDgtE4YD8RVmsKK/1q4GbfRobeM/dN3dBWA91RW/nWrZfavK/wBN8kSZ/wCWOcY/GrTuQ1YsUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcV8PiV1vxfH2GpM/wD31n/Cu1rivAI3eIPGEo+4dQ2cdMqDn+dRL4kXH4ZHa0UUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEV1bw3dvJb3USSwSDa6OMhh6EVwfgLQtPl0Zmt5J7LUYLiaG5a3l2upDkBGznIAC4z07d69Brm9X8JWl9qD39pdXmm38gxJLaSbfN/31IwaiUbtMuErK1zmdMv5JRNJYLdadZ3LHZdpayXlzdqCRu8zkL3wCDin6Nq2meG4btSrXWsXFwwQSOGuJFJATznzhOTjBI4xxniqM+tHw/4Om8OahK9lqNuywJLggSwNIAZI26Z2k+4xXTxeGVs9Fl0+O/t4dFYFpGEAErR9SDJnHT+LGcfnWSu9jaVlvsTro93cxPdeJ9UkEeN7WttIYIIh1wzDDNj1Jx7VQtD4UmONN0mS8A6Sw2cjA/SQjB+uaq6lfvr95pYa3dfDLXSRKHO171v4WCnkxAgE+o56Cu/VQqhVACgYAHarSUtjNtx3KFhdMRHCunXcESjaGk2YAH0YmtCqmqXZs7XfHH5szsscUecbnY4AJ7DuT6A1VgkvY9Xit57iKVXheV1WLaEwVC45J5yevoau9tCLX1NWiszXdTbS47V1hMomnWIgBiQD1IABPAyfwpthrEdzJOJlNsqzGKIS/Kz4QOTg9OD0PPHOOlHOr2DldrmrRVWbULSGSSOS5iEsa73TdlgOO3XuPzHrVW51qGOaGKCKa5aVUYGLbgB87ckkddrfl9KHJISi2alFZVvrMU15bw7AizW6zhmcAjJAAx756557Vq0009gaa3Ciis2813SbEkXmp2UJHZ5lB/LNDdtwSb2NKkZsVzb+OvDCHDaza5zjgk/yFTW/jLw5cNiPWrHP+1KF/nilzx7j5JdjeDA96Wq1te2d0M2tzBMPWOQN/KrGBTQhaKBRTEFFFIzBevSgCG+uorGynurhgsMKGRyewAzXNfDO3kTw19tuF2z6lPJfOP8AfPH6AH8ay/E983i/Uh4a0aTdZKwfUbyM5VFB/wBWD3Ykf55rvLeGO2t44IVCRRqERR0AAwBWafNK/RGjXLG3VklFFFaGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBXvrK1v4DDe28VxEf4ZEDD9a5W88I6gun3Gm6ZrjxaXNG0X2a5hE3lqRjCvkNjHQHNdlRUuKe5UZOOx55okd14aeNL/w1dXc0CmKO8sXEquvqI2b92TgZAxWxNqviDVoHi0jSZNNLDH2rUSo2f7sakkn68V1dFJQtpcpzvq0eavqPiXR7C3tdY0Se5+ysHjvrB/OJIyMsjcnOTnp14xT9P8AGmirezTX2ozwzXKpHNHeWjx7VXf8qbc7eW7k9DzzXo9NkjSVSsiK6nqGGRU+zfRj9onujgNP1yxWYbfEmlzRpkQPPcEtCD3Kt99scZJH065meXw/cWbLqGtaVI/WLdOsir8wZickbixHJ444GO/Uy6Bo8xzNpOnyH/btkP8ASoh4Z0EHI0TSwfX7JH/hS9m9h+0W5xl7rPh3zJ2vPE0LGZtxWziJKnKn5SN3XYvX+6MYqa28Z6THtGm6ZrOqTBg4kS1wMhdo9AAAcAY/Xmu6ttOsbX/j1s7aHH/POJV/kKtU1Ta1E6ifQ88g1PW5JRJpHgdLdwflmu5UQr+GAR+Bq39h8dajg3Wq6bpcZ6raw+aw/Fv8a7iimqfmJ1OyON/4QOG751zWNW1P1SScpH/3yv8AjV618C+GbX/V6Nasf+moMn/oRNdJRVckewvaS7mbHoOkRrtTSrFR0wLdP8KhuPDGhXAxNo+nt7/Z1H9K2KKfKuxPM+5yk3w98Lykn+ykjPrHI6Y/I1EPAsNv/wAgzWtassdFS6LIPwINdhRU+zj2K9pLuca/h7xPCc2ni2Rh/dntEb9aadO8cKPl1vTX/wB62x/IV2lFL2a7v7x+0fZfccUNP8dEY/tnSkHqICSPzFJ/wh+q6kuzxJ4kurq3P3re2QQI3sSOSK7ain7NB7R9Cjo+k2OjWYtdMto7eAHO1B1PqT1J9zV6iirSsZt33CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A Baker's cyst is a fluid-filled sac that forms at the back of the knee.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4003=[""].join("\n");
var outline_f3_58_4003=null;
var title_f3_58_4004="Acquired ichthyosis 1";
var content_f3_58_4004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acquired ichthyosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adherent, \"fish-like\" scales are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4004=[""].join("\n");
var outline_f3_58_4004=null;
var title_f3_58_4005="Technique of through-knee amputation";
var content_f3_58_4005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Technique of through-knee amputation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 700px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4005=[""].join("\n");
var outline_f3_58_4005=null;
var title_f3_58_4006="Potassium phosphate: Pediatric drug information";
var content_f3_58_4006=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium phosphate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=see_link\">",
"    see \"Potassium phosphate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/30/1508?source=see_link\">",
"    see \"Potassium phosphate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neutra-Phos&reg;-K [OTC] [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1032487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phosphate Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Potassium Salt",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider the contribution of potassium when determining the appropriate phosphate replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Phosphorus Estimated Average Requirement (EAR): Oral: 3.2 mmol/day (adequate intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance:",
"     </b>",
"     I.V.: 0.8-1.5 mmol/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1032510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=see_link\">",
"      see \"Potassium phosphate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider the contribution of potassium when determining the appropriate phosphate replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Phosphorus - Recommended Daily Allowance (RDA) and Estimated Average Requirement (EAR):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 3.2 mmol/day (adequate intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 8.9 mmol/day (adequate intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     RDA: 14.8 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 12.3 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     RDA: 16.1 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 13.1 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     RDA: 40.3 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 34 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-30 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     RDA: 22.6 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 18.7 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypophosphatemia:",
"     </b>",
"     Hypophosphatemia does not necessarily equate with phosphate depletion. Hypophosphatemia may occur in the presence of low, normal, or high total body phosphate and conversely, phosphate depletion may exist with normal, low, or elevated levels of serum phosphate (Gaasbeek, 2005). It is difficult to provide concrete guidelines for the treatment of severe hypophosphatemia because the extent of total body deficits and response to therapy are difficult to predict. Aggressive doses of phosphate may result in a transient serum elevation followed by redistribution into intracellular compartments or bone tissue. Various regimens for replacement of phosphate in adults have been studied. The regimens below have only been studied in adult patients, however, many institutions have used them in children safely and successfully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     I.V. doses may be incorporated into the patient's maintenance I.V. fluids; intermittent I.V. infusion should be reserved for severe depletion situations.",
"     <b>",
"      Note:",
"     </b>",
"     Doses listed as mmol of",
"     <b>",
"      phosphate",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Intermittent I.V. infusion: It is recommended that repletion of severe hypophosphatemia be done I.V. because large doses of oral phosphate may cause diarrhea and intestinal absorption may be unreliable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     There are no prospective studies of parenteral phosphate replacement in children. The following weight-based guidelines for adult dosing may be cautiously employed in pediatric patients. Guidelines differ based on degree of illness, use of TPN, and severity of hypophosphatemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     General replacement guidelines (Lentz, 1978):",
"     <b>",
"      Note:",
"     </b>",
"     The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia and lowered by 25% to 50% if the patient is hypercalcemic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Low dose: 0.08 mmol/kg over 6 hours; use if losses are recent and uncomplicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intermediate dose: 0.16-0.24 mmol/kg over 4-6 hours; use if serum phosphorus level 0.5-1 mg/dL (0.16-0.32 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     High dose: 0.36 mmol/kg over 6 hours; use if serum phosphorus &lt;0.5 mg/dL (&lt;0.16 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Patients receiving TPN (Clark, 1995):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Low dose: 0.16 mmol/kg over 4-6 hours; use if serum phosphorus level 2.3-3 mg/dL (0.73- 0.96 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intermediate dose: 0.32 mmol/kg over 4-6 hours; use if serum phosphorus level 1.6-2.2 mg/dL (0.51-0.72 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     High dose: 0.64 mmol/kg over 8-12 hours; use if serum phosphorus &lt;1.5 mg/dL (&lt; 0.5 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Critically ill adult trauma patients receiving TPN (Brown, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Low dose: 0.32 mmol/kg over 4-6 hours; use if serum phosphorus level 2.3-3 mg/dL (0.73-0.96 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Intermediate dose: 0.64 mmol/kg over 4-6 hours; use if serum phosphorus level 1.6-2.2 mg/dL (0.51-0.72 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     High dose: 1 mmol/kg over 8-12 hours; use if serum phosphorus &lt;1.5 mg/dL (&lt;0.5 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Alternative method in critically ill patients (Kingston, 1985):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Low dose: 0.25 mmol/kg over 4 hours; use if serum phosphorus level 0.5-1 mg/dL (0.16-0.32 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderate dose: 0.5 mmol/kg over 4 hours; use if serum phosphorus level &lt;0.5 mg/dL (&lt;0.16 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     Adults: 15 mmol/dose over 2 hours; use if serum phosphorus &lt;2 mg/dL (0.65 mmol/L); may repeat in 6- to 8-hour intervals if repeat serum phosphorus (at least 6 hours postdose) &lt;2 mg/dL (0.65 mmol/L); not to exceed 45 mmol/24 hours (Rosen, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &lt; 25 kg: 0.5-1.5 mmol/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 25-45 kg: 0.5-1 mmol/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: I.V.: 50-70 mmol/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: Potassium 4.4 mEq and phosphorus 3 mmol per mL (5 mL, 15 mL, 50 mL) [equivalent to potassium 170 mg and elemental phosphorus 93 mg per mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1032514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: For intermittent I.V. infusion: Peripheral line: Dilute to a maximum concentration of 0.05 mmol/mL; Central line: Dilute to a maximum concentration of 0.12 mmol/mL (maximum concentrations were determined with consideration for maximum potassium concentrations); maximum rate of infusion: 0.06 mmol/kg/hour; do",
"     <b>",
"      not",
"     </b>",
"     infuse with calcium-containing I.V. fluids",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F212089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      10",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, LR;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Diltiazem, enalaprilat, esmolol, famotidine, labetalol, micafungin, nicardipine, nitroprusside, telavancin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amiodarone, caspofungin, ciprofloxacin, doripenem, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Drotrecogin alfa.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Aminophylline, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Magnesium sulfate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1032507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Phosphate salts may precipitate when mixed with calcium salts; solubility is improved in parenteral nutrition solutions which contain amino acids; check with a pharmacist to determine compatibility",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1032488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of hypophosphatemia; source of phosphate in large volume I.V. fluids",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Per JCAHO recommendations, concentrated electrolyte solutions should not be available in patient care areas.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Consider special storage requirements for intravenous potassium salts; I.V. potassium salts have been administered IVP in error, leading to fatal outcomes.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Safe Prescribing: Because inorganic phosphate exists as monobasic and dibasic anions, with the mixture of valences dependent on pH, ordering by mEq amounts is unreliable and may lead to large dosing errors. In addition, I.V. phosphate is available in the sodium and potassium salt; therefore, the content of these cations must be considered when ordering phosphate. The most reliable method of ordering I.V. phosphate is by millimoles, then specifying the potassium or sodium salt. For example, an order for 15 mmol of phosphate as potassium phosphate in one liter of normal saline.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F212088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, chest pain, ECG changes, edema, heart block,  hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Listlessness, mental confusion, tetany (with large doses of phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, stomach pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urine output decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paralysis, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1032490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phosphate (salts) or any component; hyperphosphatemia, hyperkalemia, hypocalcemia, hypomagnesemia, severe renal impairment, severe tissue trauma, heat cramps, CHF, patients with phosphate kidney stones",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3458761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment, patients receiving potassium-sparing drugs (potassium salt forms), patients with adrenal insufficiency, cirrhosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1032491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral",
"     <b>",
"      potassium",
"     </b>",
"     salt forms should be administered only in patients with adequate urine flow; must be diluted before I.V. use and infused slowly, and patients must be on a cardiac monitor during intermittent infusions",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: May enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7828643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Phosphorus requirements are the same in pregnant and nonpregnant women (IOM, 1997). Although this product is not used for potassium supplementation, adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, pre-eclampsia; may be more likely to develop hyperkalemia) (IOM, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1032515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, calcium, phosphorus, renal function, reflexes; cardiac monitor (when intermittent infusion or high-dose I.V. replacement of potassium salts needed)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3458843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     There is a diurnal variation with the nadir at 1100, plateau at 1600, and peak in the early evening (Gaasbeek, 2005); 1 mmol/L phosphate = 3.1 mg/dL phosphorus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Newborns: 4.2-9 mg/dL phosphorus (1.36-2.91 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     6 weeks to 18 months: 3.8-6.7 mg/dL phosphorus (1.23-2.16 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     18 months to 3 years: 2.9-5.9 mg/dL phosphorus (0.94-1.91 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     3-15 years: 3.6-5.6 mg/dL phosphorus (1.16-1.81 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;15 years: 2.5-5 mg/dL phosphorus (0.81-1.62 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hypophosphatemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate: 1-2 mg/dL phosphorus (0.32-0.65 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe: &lt;1 mg/dL phosphorus (&lt;0.32 mmol/L phosphate)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3458762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phosphorus is an essential mineral that is usually found in nature combined with oxygen as phosphate. It participates in bone deposition, calcium metabolism, as part of molecules that regulate many coenzymes, steps in the clotting cascade, and functions of the immune system. It is a component of the lipid  bilayer of cell membranes in the form of phospholipids and of other intracellular compounds like nucleic acids and nucleoproteins. It acts as a buffer for the maintenance of plasma and urinary pH.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12734896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination: Execreted in the urine with over 80% to 90% of dose reabsorbed by the kidney",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3459425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each mmol of phosphate contains 31 mg elemental phosphorus; 1 mmol/L phosphate = 3.1 mg/dL phosphorus; cow&rsquo;s milk is a good source of phosphate with 1 mg elemental (0.032 mmol) elemental phosphate per mL",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     With orders for I.V. phosphate, there is considerable confusion associated with the use of millimoles (mmol) versus milliequivalents (mEq) to express the phosphate requirement. Because inorganic phosphate exists as monobasic and dibasic anions, with the mixture of valences dependent on pH, ordering by mEq amounts is unreliable and may lead to large dosing errors. In addition, I.V. phosphate is available in the sodium and potassium salt; therefore, the content of these cations must be considered when ordering phosphate. The most reliable method of ordering I.V. phosphate is by millimoles, then specifying the potassium or sodium salt.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brown KA, Dickerson, RN, Morgan, RN, et al, &ldquo;A New Graduated Dosing Regimen for Phosphorus Replacement in Patients Receiving Nutrition Support,&rdquo;",
"      <i>",
"       JPEN",
"      </i>",
"      , 2006, 30(3):209-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/58/4006/abstract-text/16639067/pubmed\" id=\"16639067\" target=\"_blank\">",
"        16639067",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark CL, Sacks GS, Dickerson RN, et al, &ldquo;Treatment of Hypophosphatemia in Patients Receiving Specialized Nutrition Support Using a Graduated Dosing Scheme: Results From a Prospective Clinical Trial,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1995, 23(9):1504-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/58/4006/abstract-text/7664552/pubmed\" id=\"7664552\" target=\"_blank\">",
"        7664552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine,&rdquo; National Academy of Sciences, Washington, DC: National Academy Press, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaasbeek A and Meinders AE, &ldquo;Hypophosphatemia: An Update on Its Etiology and Treatment,&rdquo; Am J Med, 2005, 118(10):1094-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/58/4006/abstract-text/16194637/pubmed\" id=\"16194637\" target=\"_blank\">",
"        16194637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kingston M and Al-Siba'i MB, \"Treatment of Severe Hypophosphatemia,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1985, 13(1):16-8",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/58/4006/abstract-text/3965243/pubmed\" id=\"3965243\" target=\"_blank\">",
"        3965243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lentz RD, Brown DM, and Kjellstrand CM, &ldquo;Treatment of Severe Hypophosphatemia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1978, 89(6):941-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/58/4006/abstract-text/102230/pubmed\" id=\"102230\" target=\"_blank\">",
"        102230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lloyd CW and Johnson CE, &ldquo;Management of Hypophosphatemia,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1988, 7(2):123-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/58/4006/abstract-text/3280219/pubmed\" id=\"3280219\" target=\"_blank\">",
"        3280219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosen GH, Boullata JI, O'Rangers EA, et al, &ldquo;Intravenous Phosphate Repletion Regimen for Critically Ill Patients With Moderate Hypophosphatemia,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1995, 23(7):1204-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/58/4006/abstract-text/7600828/pubmed\" id=\"7600828\" target=\"_blank\">",
"        7600828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12985 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4006=[""].join("\n");
var outline_f3_58_4006=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212067\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032487\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444796\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032510\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212056\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212041\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032514\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212089\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032507\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032488\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212091\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212088\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032490\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3458761\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032491\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299925\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212049\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212052\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7828643\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032515\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3458843\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3458762\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12734896\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3459425\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12985\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12985|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=related_link\">",
"      Potassium phosphate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/30/1508?source=related_link\">",
"      Potassium phosphate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_58_4007="Split S2";
var content_f3_58_4007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Splitting of the second heart sound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 462px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wide splitting of second heart sound (S2) may be due to delayed closure of pulmonic valve as in right bundle branch block, pulmonic stenosis, and atrial septal defect, or to early closure of aortic valve as in mitral regurgitation and ventricular septal defect. In atrial septal defect, splitting is both wide and fixed.",
"    <div class=\"footnotes\">",
"     S1: first heart sound; A2: aortic valve closure sound; P2: pulmonic valve closure sound; T1: tricuspid valve closure sound; M1: mitral valve closure sound.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Shaver JA, Leonard JJ, Leon DF. Auscultation of the Heart. Examination of the Heart, Part 4. American Heart Association, Dallas 1990. Copyright &copy;1990, American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4007=[""].join("\n");
var outline_f3_58_4007=null;
var title_f3_58_4008="Light microscopy yolk sac tumor";
var content_f3_58_4008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Yolk sac tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a testicular yolk sac tumor showing one of its many histologic patterns. The cells show less atypia than do those of embryonal carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Weinstein, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4008=[""].join("\n");
var outline_f3_58_4008=null;
var title_f3_58_4009="Overview of the presentation and classification of acute lymphoblastic leukemia in children";
var content_f3_58_4009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/58/4009/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/58/4009/contributors\">",
"     Terzah M Horton, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/58/4009/contributors\">",
"     C Philip Steuber, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/58/4009/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/58/4009/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/58/4009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/58/4009/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/58/4009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute leukemia, the most common form of cancer in children, comprises approximately 30 percent of all childhood malignancies, with acute lymphoblastic leukemia (ALL) being five times more common than acute myeloid leukemia (AML) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/1\">",
"     1",
"    </a>",
"    ]. Each year in the United States approximately 2500 to 3500 new cases of ALL are diagnosed in children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival rates for ALL have improved dramatically since the 1980s, with a current five-year overall survival rate estimated at greater than 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. This improvement is in large part because of treatment of large numbers of children with sequential standardized research protocols. Approximately 75 to 80 percent of children with newly diagnosed ALL participate in clinical research trials, the goals of which are to improve clinical outcome and to minimize acute toxicities and late-occurring adverse events.",
"   </p>",
"   <p>",
"    The presentation and classification of ALL in children are reviewed here. The treatment of childhood ALL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, approximately 2500 to 3500 new cases of ALL are diagnosed in children each year in the United States with an incidence of 2.8 cases per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/2,3,7\">",
"     2,3,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears the incidence of childhood leukemia is increasing as demonstrated by the two following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that used data from 63 European population-based cancer registries of children diagnosed with cancer, the incidence of leukemia including ALL increased by an average of 1.4 percent from 1970 to 1999 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from Great Britain, the incidence of leukemia (mostly attributable to ALL) has steadily increased from 3.83 to 4.61 per 100,000 persons by sex and age from the five-year period of 1971 to 1975 and 1996 to 2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a study from four Nordic countries (Denmark, Finland, Norway, and Sweden) reported that the incidence of childhood ALL remained stable at an approximate rate of 3.3 cases per 100,000 children below 15 years of age from 1983 to 2002 after an increase in incidence between 1975 and 1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peak incidence occurs between two and five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/10-13\">",
"     10-13",
"    </a>",
"    ], and it occurs more commonly among boys than girls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. In the United States, ALL occurs two times more commonly among white than black children and the highest incidence is among Hispanic whites [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Certain genetic and immunodeficiency syndromes (eg, Down syndrome, Neurofibromatosis type 1, Bloom syndrome, and ataxia telangiectasia) also place children at higher risk for ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. An increased risk of ALL associated with higher birth weight has also been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/17\">",
"     17",
"    </a>",
"    ]. Studies of the relationship between childhood ALL,",
"    <span class=\"nowrap\">",
"     urban/rural",
"    </span>",
"    status and population density, as well as other possible etiologic factors (eg, environmental exposures, abnormal immune response to common infection(s)) have yielded inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/18-26\">",
"     18-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EARLY SIGNS AND SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting symptoms of ALL are nonspecific (eg, fever, bleeding, bone pain, lymphadenopathy). Unexplained persistence of any of these common signs or symptoms should prompt consideration of malignancy as a possible cause. The characteristics of common presenting signs or symptoms of leukemia that are suggestive of malignancy are discussed briefly below and in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link\">",
"     \"Clinical assessment of the child with suspected cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Musculoskeletal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although bone pain occurs commonly among children, particularly adolescents, it may be a symptom of ALL. Early bone marrow examination should be considered in any child who has persistent bone pain and peripheral blood abnormalities. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bone pain, particularly affecting the long bones, and caused by leukemic involvement of the periosteum, is a presenting symptom in 21 to 38 percent of cases of acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Bone pain also results from aseptic osteonecrosis because of malignant cell necrosis in the bone marrow involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Radiographic changes are present in as many as one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/27\">",
"     27",
"    </a>",
"    ]. Young children with such pain may present with limp or refusal to bear weight [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of bone marrow aspirate smears\", section on 'Bone marrow necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Musculoskeletal pain associated with acute leukemia, particularly if it occurs in the joints, may be mistaken for rheumatologic pain. Features that may be helpful in differentiating leukemic from rheumatologic musculoskeletal pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical assessment of the child with suspected cancer\", section on 'Bone and joint pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon (&lt;5 percent of cases), leukemia involving the central nervous system (CNS) can present with symptoms of increased intracranial pressure, including headache, vomiting, lethargy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nuchal rigidity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/33\">",
"     33",
"    </a>",
"    ]. Rarely, leukemia can present with cranial nerve abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of children with ALL present with lymphadenopathy, which is one of the indications of extramedullary leukemic spread [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/14\">",
"     14",
"    </a>",
"    ]. As a general rule, a lymph node is considered enlarged if it is &gt;10 mm in its greatest diameter. Exceptions to this rule include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Epitrochlear nodes are enlarged if they are &gt;5 mm.",
"     </li>",
"     <li>",
"      Inguinal nodes are enlarged if they are &gt;15 mm in greatest diameter.",
"     </li>",
"     <li>",
"      Cervical nodes are enlarged if they are &gt;20 mm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lymphadenopathy associated with malignancy usually is nontender, firm, rubbery, and matted. Persistent or progressive lymphadenopathy that does not respond to antibiotic therapy suggests the need for more extensive evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical assessment of the child with suspected cancer\", section on 'Lymphadenopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the child with peripheral lymphadenopathy\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Testicular enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, painless unilateral testicular enlargement can be a presenting sign of ALL. Any persistent, painless, solid testicular mass should be referred for biopsy by a pediatric surgeon after evaluation by ultrasound. When testicular leukemia is suspected, bilateral wedge biopsies are preferred to decrease sampling error. Histologic interpretation can be challenging and requires the ability to differentiate leukemic lymphoblasts from reactive lymphocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mediastinal mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents with ALL may present with many of the features of non-Hodgkin lymphoma. Distinguishing between these two disorders can sometimes be difficult. T-cell ALL commonly occurs in older boys who present with high initial white blood cell (WBC) counts and a large mediastinal mass. Patients who present with features of lymphoma, such as mediastinal mass and lymphadenopathy, often have significant bone marrow involvement. Malignant lymphoblasts found in T-cell lymphoblastic lymphoma are indistinguishable from T-cell ALL; by convention, children having more extensive bone marrow involvement are classified as having leukemia (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A large anterior mediastinal mass can narrow the trachea, causing respiratory distress. Such masses also can be associated with pleural effusions, further compromising respiratory function. In addition, a mediastinal mass can obstruct the superior vena cava, resulting in superior vena cava syndrome, which is manifest as pain, dysphagia, dyspnea, or swelling of the neck, face, and upper limbs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link\">",
"     \"Malignancy-related superior vena cava syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Peripheral blood abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with ALL have anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia with either normal or depressed WBC counts and lymphoblasts on peripheral smear (",
"    <a class=\"graphic graphic_picture graphicRef57831 \" href=\"UTD.htm?24/53/25439\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65474 \" href=\"UTD.htm?41/54/42848\">",
"     picture 2",
"    </a>",
"    ). Approximately 50 percent of children have WBC counts",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL,",
"    </span>",
"    and 20 percent have an initial leukocyte count",
"    <span class=\"nowrap\">",
"     &gt;50,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/14\">",
"     14",
"    </a>",
"    ]. Approximately one-half of children with ALL present with bleeding (including petechiae and purpura) and three-quarters have a platelet count",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL",
"    </span>",
"    at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest the need for bone marrow examination, which should be performed for the following indications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atypical cells in the peripheral blood",
"     </li>",
"     <li>",
"      Unexplained depression of more than one peripheral blood element",
"     </li>",
"     <li>",
"      Unexplained lymphadenopathy or hepatosplenomegaly associated with cytopenias",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the presenting signs and symptoms of ALL are nonspecific. A variety of malignant and nonmalignant conditions must be considered in the differential diagnosis. They include [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/14,36\">",
"     14,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Juvenile idiopathic arthritis (see appropriate topic reviews)",
"     </li>",
"     <li>",
"      Osteomyelitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link&amp;anchor=H27#H27\">",
"       \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Differential diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Epstein-Barr virus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"       \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Idiopathic thrombocytopenic purpura (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"       \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pertussis, parapertussis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Aplastic anemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link\">",
"       \"Acquired aplastic anemia in children and young adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute infectious lymphocytosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3274?source=see_link\">",
"       \"Approach to the patient with lymphocytosis or lymphocytopenia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other malignancies with bone marrow involvement (eg, neuroblastoma, retinoblastoma, rhabdomyosarcoma, and Ewing sarcoma) (see appropriate topic reviews)",
"     </li>",
"     <li>",
"      Hypereosinophilic syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis and classification of leukemia are based upon specialized tests that are performed on cells derived from a bone marrow aspirate or tissue biopsy specimens. When clinical circumstances preclude bone marrow examination, the diagnosis can be made from cells obtained from peripheral leukopheresis or pleural effusions. The diagnosis of CNS leukemia requires cytologic confirmation of the presence of leukemic cells in the cerebrospinal fluid.",
"   </p>",
"   <p>",
"    ALL can present clinically as either a mass lesion or as leukemia. Although the distinction in some patients is arbitrary, ALL is the preferred term when the bone marrow contains more than 25 percent lymphoblasts, whereas lymphoma is the preferred term when the process is confined to a mass lesion with minimal or no blood and bone marrow involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are suspected of having leukemia should be referred to a pediatric cancer center for evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/38\">",
"     38",
"    </a>",
"    ]. This evaluation will include clinical examination, and bone marrow aspiration and biopsy, which will diagnose ALL and determine the leukemia phenotype as well as the presence or absence of cytogenetic abnormalities. This initial information will be used to assign the patient to a treatment group based upon risk stratification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37753?source=see_link\">",
"     \"Risk group stratification and prognosis for acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial laboratory evaluation also includes assessment for possible disease complications. As an example, patients with a high tumor burden may have increased serum uric acid concentration, which can cause uric acid nephropathy and renal failure if not addressed before chemotherapy is started. The initial laboratory evaluation should include a complete blood count with manual differential, PT, PTT, electrolytes, uric acid, and renal and liver function tests. Baseline viral titers, including cytomegalovirus, Epstein Barr virus, human immunodeficiency virus, hepatitis B virus, and varicella zoster virus often are included.",
"   </p>",
"   <p>",
"    Several abnormalities, including hepatic dysfunction, coagulation abnormalities, hypercalcemia, hypocalcemia, hyperkalemia, and hyperphosphatemia, may be noted [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood ALL is a heterogeneous disease that is classified according to morphologic, immunologic, biochemical, and cytogenetic features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morphologic classification of ALL often is based upon evaluation of the bone marrow aspirate using the French-American-British (FAB) system [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of bone marrow aspirate smears\", section on 'Acute lymphoblastic leukemia'",
"    </a>",
"    .) According to this system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      L1 lymphoblasts are small cells with scant cytoplasm, condensed nuclear chromatin, and indistinct nucleoli (",
"      <a class=\"graphic graphic_picture graphicRef72835 \" href=\"UTD.htm?36/12/37062\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57831 \" href=\"UTD.htm?24/53/25439\">",
"       picture 1",
"      </a>",
"      ). Most children with ALL cases (85 to 89 percent) are classified as having FAB L1 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      L2 lymphoblasts are larger cells with a moderate amount of cytoplasm, dispersed chromatin, and multiple nucleoli (",
"      <a class=\"graphic graphic_picture graphicRef52878 \" href=\"UTD.htm?13/1/13332\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef65474 \" href=\"UTD.htm?41/54/42848\">",
"       picture 2",
"      </a>",
"      ). In some studies, L2 has been associated with worse prognosis than has L1 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/40,42\">",
"       40,42",
"      </a>",
"      ]. However, when patients are stratified according to age, sex, and initial WBC, differences in prognosis between L1 and L2 are no longer observed [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/41\">",
"       41",
"      </a>",
"      ]. Eleven to 14 percent of cases of ALL in children are classified as FAB L2 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      L3 lymphoblasts have deep cytoplasmic basophilia with prominent cytoplasmic vacuolation (",
"      <a class=\"graphic graphic_picture graphicRef77240 \" href=\"UTD.htm?23/17/23830\">",
"       picture 5",
"      </a>",
"      ). L3 morphology correlates with a more guarded prognosis. The L3 cell usually has mature B-cell characteristics and often is treated using drugs effective for highly aggressive B-cell lymphoma variants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link\">",
"       \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"      </a>",
"      .) Less than 1 percent of cases of ALL in children are classified as FAB L3 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemia cells in ALL also are classified according to immunophenotype using an extensive panel of monoclonal antibodies to cell surface \"cluster of differentiation\" (CD) markers (",
"    <a class=\"graphic graphic_table graphicRef65155 \" href=\"UTD.htm?15/31/15867\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Approximately 70 to 80 percent of cases of childhood ALL are of B-precursor lineage (ie, precursor B-cell leukemia or early pre-B cell ALL). B-precursor leukemia typically is CD10+, CD19+, and sometimes CD20+. Leukemic lymphoblasts with the L3 morphology (described above) usually have markers for mature-B-cell ALL (CDs 10&plusmn; 19,20,22,25, and surface immunoglobulin [sIg]).",
"   </p>",
"   <p>",
"    Cases of T-cell ALL (ie, precursor T lymphoblastic leukemia), which comprise 15 to 17 percent of all cases of ALL, are positive for CDs 2, 3, 4, 5, 7, and 8. Approximately 10 percent of those with T-cell ALL have a distinct immunophenotype (CD8-, CD5dim) and gene expression signature, consistent with an early T-cell precursor phenotype (ETP ALL) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/43\">",
"     43",
"    </a>",
"    ]. These patients have a high rate of remission failure (57 to 75 percent) and a poor overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/44\">",
"     44",
"    </a>",
"    ]. Whole genome sequencing suggests that ETP ALL has many of the genetic features of myeloid stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/45\">",
"     45",
"    </a>",
"    ]. Optimal treatment for this subtype of T-cell ALL has yet to be determined.",
"   </p>",
"   <p>",
"    The expression of markers on the leukemic lymphoblasts does not strictly correlate with normal lymphoid maturation. Some B-precursor ALL cells, for example, express myeloid markers (ie, markers more typical of the granulocytic series) in addition to classic B-lymphocyte markers. Although this does not affect long-term prognosis or risk group assignment, it is one of the reasons why immunophenotyping should not be used as the sole means of leukemia classification [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cytogenetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytogenetic studies from ALL lymphoblasts also are used to classify ALL and commonly are used for the assignment to a particular treatment risk group. Standard karyotype analysis frequently is complemented with molecular analysis of known predictive chromosomal abnormalities using fluorescence in situ hybridization (FISH) and other molecular techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both numerical and structural abnormalities of the chromosomes in ALL are associated with prognosis and influence selection of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/48\">",
"     48",
"    </a>",
"    ]. The following is a summary of these abnormalities, which are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37753?source=see_link\">",
"     \"Risk group stratification and prognosis for acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with lymphoblasts exhibiting hyperdiploidy (54 to 58 chromosomes) have the best prognosis, particularly if associated with the combined trisomies of chromosomes 4, 10, or 17 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Such patients usually do well and require less toxic therapies. In contrast, extreme hyperdiploidy (59 to 84 chromosomes) or hypodiploidy (fewer than 45 chromosomes) is associated with poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Patients whose disease manifests these aberrations require more aggressive (and consequently more toxic) therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/48,49,53\">",
"     48,49,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Structural abnormalities (ie, specific translocations) also are associated with outcome and can influence treatment assignment. Commonly recognized structural abnormalities associated with a poor outcome include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      t(9;22)",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      translocation (Philadelphia chromosome) &mdash; Present in 3 to 4 percent of ALL patients; often occurs in older children.",
"     </li>",
"     <li>",
"      t(4;11)",
"      <span class=\"nowrap\">",
"       MLL/AF4",
"      </span>",
"      rearrangement &mdash; Present in 5 percent of pediatric ALL patients and 60 percent of infant ALL patients.",
"     </li>",
"     <li>",
"      t(8;14)",
"      <span class=\"nowrap\">",
"       MYC/IGH",
"      </span>",
"      translocation is associated with mature B-cell ALL with FAB L3 morphology. This translocation is present in 1 percent of ALL patients (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link\">",
"       \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More aggressive treatment regimens are recommended for children with any of these findings. Addition of tyrosine kinase inhibitor therapy should be considered in patients with t(9;22). Patients with the t(4;11) MLL rearrangement have a significantly poorer treatment outcome than do those without this abnormality and are treated with more intensive chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some structural abnormalities are associated with favorable prognosis. They include the t(12;21)",
"    <span class=\"nowrap\">",
"     ETV6/RUNX1",
"    </span>",
"    (formerly referred to as",
"    <span class=\"nowrap\">",
"     TEL/AML1)",
"    </span>",
"    rearrangement in B-precursor ALL, which occurs in 20 to 25 percent of cases of childhood ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. In addition, one study showed favorable outcome in T cell ALL patients with t(10;14) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytogenetics must be considered in the context of other risk factors. As an example, in one prospective study of 44 children with high-risk ALL, as determined by age, WBC count, and immunophenotype, cytogenetic abnormalities did not independently predict outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4009/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37753?source=see_link\">",
"     \"Risk group stratification and prognosis for acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics t (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/40/24194?source=see_link\">",
"       \"Patient information: Leukemia in children (The Basics)\"",
"      </a>",
"      )opic",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children. The peak incidence occurs between 2 and 5 years of age. Children with certain genetic and immunodeficiency syndromes are at increased risk. These include Down syndrome, Neurofibromatosis type 1, Bloom syndrome, and ataxia telangiectasia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common presenting symptoms of ALL are nonspecific: fever, infection, bleeding, bone pain, or lymphadenopathy. Unexplained persistence of any of these common signs or symptoms should prompt consideration of malignancy as a possible cause. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Early signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis and classification of leukemia are based upon specialized tests (morphology, immunophenotype, and cytogenetics) that are performed on leukemic lymphoblasts or myeloblasts derived from bone marrow or tissue biopsy specimens. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who are suspected of having leukemia should be referred to a pediatric cancer center for evaluation and treatment. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Initial evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link\">",
"       \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEER Cancer Statistic Review, 1973-1999. National Cancer Institute, Bethesda, MD, 2000. p.467.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/2\">",
"      Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995; 75:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/3\">",
"      Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/4\">",
"      Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/5\">",
"      Gatta G, Capocaccia R, Stiller C, et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005; 23:3742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/6\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/7\">",
"      McNeil DE, Cot&eacute; TR, Clegg L, Mauer A. SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol 2002; 39:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/8\">",
"      Steliarova-Foucher E, Stiller C, Kaatsch P, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet 2004; 364:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/9\">",
"      Shah A, Coleman MP. Increasing incidence of childhood leukaemia: a controversy re-examined. Br J Cancer 2007; 97:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/10\">",
"      Svendsen AL, Feychting M, Klaeboe L, et al. Time trends in the incidence of acute lymphoblastic leukemia among children 1976-2002: a population-based Nordic study. J Pediatr 2007; 151:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/11\">",
"      Swensen AR, Ross JA, Severson RK, et al. The age peak in childhood acute lymphoblastic leukemia: exploring the potential relationship with socioeconomic status. Cancer 1997; 79:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/12\">",
"      McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 1997; 15:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/13\">",
"      Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34.",
"     </a>",
"    </li>",
"    <li>",
"     Margolin JF, Steuber CP, Poplack DG. Acute Lymphoblastic Leukemia. In: Principles and Practice of Pediatric Oncology, 4th ed, Pizzo PA, Poplack DG (Eds), Lippincott-Raven, Philadelphia 2001. p.489.",
"    </li>",
"    <li>",
"     Gurney JG, Bondy ML. Epidemiologic research methods and childhood cancer. In: Principles and Practice of Pediatric Oncology, 4th ed, Pizzo PA, Poplack DG (Eds), Lippincott-Raven, Philadelphia 2001. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/16\">",
"      Buffler PA, Kwan ML, Reynolds P, Urayama KY. Environmental and genetic risk factors for childhood leukemia: appraising the evidence. Cancer Invest 2005; 23:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/17\">",
"      Hjalgrim LL, Rostgaard K, Hjalgrim H, et al. Birth weight and risk for childhood leukemia in Denmark, Sweden, Norway, and Iceland. J Natl Cancer Inst 2004; 96:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/18\">",
"      Adelman AS, McLaughlin CC, Wu XC, et al. Urbanisation and incidence of acute lymphocytic leukaemia among United States children aged 0-4. Br J Cancer 2005; 92:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/19\">",
"      Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006; 6:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/20\">",
"      Kroll ME, Draper GJ, Stiller CA, Murphy MF. Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics. J Natl Cancer Inst 2006; 98:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/21\">",
"      Kroll ME, Swanson J, Vincent TJ, Draper GJ. Childhood cancer and magnetic fields from high-voltage power lines in England and Wales: a case-control study. Br J Cancer 2010; 103:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/22\">",
"      Kheifets L, Ahlbom A, Crespi CM, et al. Pooled analysis of recent studies on magnetic fields and childhood leukaemia. Br J Cancer 2010; 103:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/23\">",
"      Urayama KY, Ma X, Selvin S, et al. Early life exposure to infections and risk of childhood acute lymphoblastic leukemia. Int J Cancer 2011; 128:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/24\">",
"      Reid A, Glass DC, Bailey HD, et al. Risk of childhood acute lymphoblastic leukaemia following parental occupational exposure to extremely low frequency electromagnetic fields. Br J Cancer 2011; 105:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/25\">",
"      Kroll ME, Stiller CA, Murphy MF, Carpenter LM. Childhood leukaemia and socioeconomic status in England and Wales 1976-2005: evidence of higher incidence in relatively affluent communities persists over time. Br J Cancer 2011; 105:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/26\">",
"      Chang JS, Tsai YW, Tsai CR, Wiemels JL. Allergy and risk of childhood acute lymphoblastic leukemia: a population-based and record-based study. Am J Epidemiol 2012; 176:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/27\">",
"      Rogalsky RJ, Black GB, Reed MH. Orthopaedic manifestations of leukemia in children. J Bone Joint Surg Am 1986; 68:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/28\">",
"      Hann IM, Gupta S, Palmer MK, Morris-Jones PH. The prognostic significance of radiological and symptomatic bone involvement in childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1979; 6:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/29\">",
"      Jonsson OG, Sartain P, Ducore JM, Buchanan GR. Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes. J Pediatr 1990; 117:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/30\">",
"      Sinigaglia R, Gigante C, Bisinella G, et al. Musculoskeletal manifestations in pediatric acute leukemia. J Pediatr Orthop 2008; 28:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/31\">",
"      K&ouml;rholz D, Bruder M, Engelbrecht V, et al. Aseptic osteonecrosis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1998; 15:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/32\">",
"      Vesterby A, Myhre Jensen O. Aseptic bone/bone marrow necrosis in leukaemia. Scand J Haematol 1985; 35:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/33\">",
"      Bleyer WA. Central nervous system leukemia. Pediatr Clin North Am 1988; 35:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/34\">",
"      Ingram LC, Fairclough DL, Furman WL, et al. Cranial nerve palsy in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Cancer 1991; 67:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/35\">",
"      Paryani SB, Donaldson SS, Amylon MD, Link MP. Cranial nerve involvement in children with leukemia and lymphoma. J Clin Oncol 1983; 1:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/36\">",
"      Simone JV, Verzosa MS, Rudy JA. Initial features and prognosis in 363 children with acute lymphocytic leukemia. Cancer 1975; 36:2099.",
"     </a>",
"    </li>",
"    <li>",
"     Brunning RD, Flandrin G, Borowitz M, et al. Precursor B lymphoblastic leukaemia/lymphoblastic lymphoma (Precursor B-cell acute lymphoblastic leukaemia). In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/38\">",
"      Corrigan JJ, Feig SA, American Academy of Pediatrics. Guidelines for pediatric cancer centers. Pediatrics 2004; 113:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/39\">",
"      Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/40\">",
"      Miller DR, Leikin S, Albo V, et al. Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukaemia (ALL). Br J Haematol 1981; 48:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/41\">",
"      Lilleyman JS, Hann IM, Stevens RF, et al. Cytomorphology of childhood lymphoblastic leukaemia: a prospective study of 2000 patients. United Kingdom Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol 1992; 81:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/42\">",
"      Lilleyman JS, Hann IM, Stevens RF. The clinical significance of blast cell morphology in childhood lymphoblastic leukaemia. Med Pediatr Oncol 1986; 14:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/43\">",
"      Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/44\">",
"      Inukai T, Kiyokawa N, Campana D, et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol 2012; 156:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/45\">",
"      Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/46\">",
"      Harrison CJ. The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia. Blood Rev 2001; 15:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/47\">",
"      Harrison CJ, Moorman AV, Barber KE, et al. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol 2005; 129:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/48\">",
"      Pui CH, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990; 76:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/49\">",
"      Heerema NA, Sather HN, Sensel MG, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (&gt; 50 chromosomes). J Clin Oncol 2000; 18:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/50\">",
"      Harris MB, Shuster JJ, Carroll A, et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 1992; 79:3316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/51\">",
"      Raimondi SC, Zhou Y, Mathew S, et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 2003; 98:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/52\">",
"      Harrison CJ, Moorman AV, Broadfield ZJ, et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 2004; 125:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/53\">",
"      Chessels JM, Swansbury GJ, Reeves B, et al. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 1997; 99:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/54\">",
"      Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102:2951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/55\">",
"      Mosquera-Caro M, Helman P, Veroff R, et al. Identification, validation, and cloning of a novel gene (OPAL1) and associated genes highly predictive of outcome in pediatric acute lymphoblastic leukemia using gene expression profiling (abstract). Blood 2003; 102:4a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/56\">",
"      Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 2004; 103:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/57\">",
"      van Delft FW, Bellotti T, Luo Z, et al. Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. Br J Haematol 2005; 130:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/58\">",
"      Holleman A, den Boer ML, de Menezes RX, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006; 107:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/59\">",
"      Kosaka Y, Koh K, Kinukawa N, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004; 104:3527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/60\">",
"      Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/61\">",
"      Loh ML, Goldwasser MA, Silverman LB, et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006; 107:4508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/62\">",
"      Schneider NR, Carroll AJ, Shuster JJ, et al. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases. Blood 2000; 96:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4009/abstract/63\">",
"      Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 2002; 87:154.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6244 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4009=[""].join("\n");
var outline_f3_58_4009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EARLY SIGNS AND SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Musculoskeletal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Testicular enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mediastinal mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Peripheral blood abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cytogenetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6244\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6244|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/53/25439\" title=\"picture 1\">",
"      Lymphoblasts FAB L1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/54/42848\" title=\"picture 2\">",
"      Lymphoblasts FAB L2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/12/37062\" title=\"picture 3\">",
"      L1 lymphoblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/1/13332\" title=\"picture 4\">",
"      L2 lymphoblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/17/23830\" title=\"picture 5\">",
"      Lymphoblasts FAB L3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6244|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/31/15867\" title=\"table 1\">",
"      Frequency ALL subtypes children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=related_link\">",
"      Acquired aplastic anemia in children and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3274?source=related_link\">",
"      Approach to the patient with lymphocytosis or lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=related_link\">",
"      Evaluation of bone marrow aspirate smears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/40/24194?source=related_link\">",
"      Patient information: Leukemia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37753?source=related_link\">",
"      Risk group stratification and prognosis for acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_58_4010="Mucosal melanoma";
var content_f3_58_4010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mucosal melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/58/4010/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/58/4010/contributors\">",
"     Richard D Carvajal, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/58/4010/contributors\">",
"     Omid Hamid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/58/4010/contributors\">",
"     Charlotte Ariyan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/58/4010/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/58/4010/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/58/4010/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/58/4010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/58/4010/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/58/4010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3306289\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanomas may arise from the mucosal epithelium lining the respiratory, alimentary, and genitourinary tracts, all of which contain melanocytes, as well as from the skin.",
"   </p>",
"   <p>",
"    Mucosal melanomas generally carry a worse prognosis than those arising from cutaneous sites. Because of the rarity of mucosal melanoma, and because of the unique biology and clinical challenges of mucosal melanoma arising from each anatomic location, our understanding of these malignancies and their optimal management remains limited.",
"   </p>",
"   <p>",
"    General aspects of mucosal melanoma, as well as the specific approach to patients with mucosal melanomas arising in the head and neck, vulvovaginal, and anorectal regions, are discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32370021\">",
"    <span class=\"h1\">",
"     MUCOSAL VERSUS CUTANEOUS MELANOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are substantial differences in mucosal as opposed to cutaneous melanomas that have important implications for patient management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32370278\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal melanomas are rare and account for approximately 1 percent of all melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/1\">",
"     1",
"    </a>",
"    ]. Mucosal melanomas arise primarily in the head and neck, anorectal, and vulvovaginal regions (55, 24, and 18 percent of cases, respectively). Rarer sites of origin include the urinary tract, gall bladder, and small intestine.",
"   </p>",
"   <p>",
"    In general, patients diagnosed with mucosal melanomas are older, with a median age of 70 years, although mucosal melanoma of the oral cavity frequently presents at a younger age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Mucosal melanoma is more common in females than males, primarily due to the development of disease in the genital tract [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the incidence of cutaneous melanoma has been increasing rapidly in the United States, the incidence of mucosal melanoma has generally remained stable over time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Cutaneous melanoma is associated with exposure to ultraviolet light, but the anatomic location of mucosal melanoma precludes ultraviolet exposure as a risk factor. No clear predisposing risk factors have been identified in this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mucosal melanomas make up a greater proportion of all melanomas diagnosed in blacks, Asians, and Hispanics when compared with melanomas occurring in whites, reflecting the much lower incidence of cutaneous melanoma in these populations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/8\">",
"     8",
"    </a>",
"    ]. While less than 2 percent of melanomas occurring in white non-Hispanic patients arise in mucosal sites, 9 percent of melanomas diagnosed in black or Hispanic patients have a mucosal origin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite a greater proportion of mucosal melanomas in blacks, Asians, and Hispanics, the absolute incidence of mucosal melanoma remains greater in whites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32370271\">",
"    <span class=\"h2\">",
"     Biology and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated 20 percent of mucosal melanomas are multifocal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/9\">",
"     9",
"    </a>",
"    ], compared with less than 5 percent of those arising in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/10\">",
"     10",
"    </a>",
"    ]. Approximately 40 percent of mucosal melanomas are amelanotic, compared with less than 10 percent of cutaneous melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Staging of mucosal melanomas varies depending upon the primary site. However, a simplified staging system, which was originally developed for melanomas of the head and neck, can be applied to all cases of mucosal melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/11\">",
"     11",
"    </a>",
"    ]. This staging system classifies tumors into three stages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; clinically localized disease",
"     </li>",
"     <li>",
"      Stage II &mdash; regional nodal involvement",
"     </li>",
"     <li>",
"      Stage III &mdash; distant metastatic involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the primary site, wide local excision of mucosal melanoma offers the best chance for prolonged disease-free survival when technically feasible. However, complete resection with negative margins is frequently difficult because of the lentiginous growth pattern frequently associated with mucosal melanoma, the multifocality of disease, and anatomic constraints.",
"   </p>",
"   <p>",
"    Most patients will ultimately develop distant metastatic disease regardless of the completeness of surgical resection. The significant disease complications that result from primary site failure must be balanced against the morbidity of a more aggressive resection. Thus patient preferences, as well as quality of life considerations, are critical in determining the extent of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3306310\">",
"    <span class=\"h1\">",
"     MUCOSAL MELANOMA OF THE HEAD AND NECK",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32357298\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal melanomas account for less than 10 percent of all melanomas arising in the head and neck region, while more than 90 percent arise in the skin. Mucosal melanomas of the head and neck commonly occur in the following locations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasal cavity (most commonly involving the turbinates and nasal wall) &mdash; 55 percent",
"     </li>",
"     <li>",
"      Paranasal sinuses (most commonly involving the maxillary and ethmoid sinuses) &mdash; 15 percent",
"     </li>",
"     <li>",
"      Oral cavity (most commonly involving the hard palate and upper alveolus) &mdash; 25 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much less commonly, mucosal melanomas arise in the pharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/18\">",
"     18",
"    </a>",
"    ], larynx [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/19\">",
"     19",
"    </a>",
"    ], or esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with sinonasal mucosal melanomas frequently present with nasal obstruction, epistaxis, or loss of smell [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Mucosal melanoma of the oral cavity typically presents as a painless bleeding mass, an area of ulceration, a region of mucosal discoloration, or with ill-fitting dentures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 60 percent of mucosal melanomas arising from the oral cavity are identified incidentally during routine dental examination. Irregular isolated areas of pigmentation within the oral mucosa must be differentiated from melanosis, a benign condition which is common in blacks and generally is symmetrical. Such lesions should be biopsied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3306317\">",
"    <span class=\"h2\">",
"     Evaluation and staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Work-up for patients with mucosal melanoma arising from the head and neck should include clinical examination with endoscopic inspection for paranasal disease, CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI of the primary site of disease, and CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PET imaging to assess for lymph node involvement or distant metastases. Regional lymph node involvement has been estimated to be present at presentation in approximately 25 percent of those with oral cavity lesions and 6 percent of those with sinonasal mucosal melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Joint Committee on Cancer (AJCC) staging system for mucosal melanoma arising from the head and neck is now generally used for this subset of disease and reflects the overwhelmingly poor prognosis of this disease (",
"    <a class=\"graphic graphic_table graphicRef56221 \" href=\"UTD.htm?37/41/38555\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71892 \" href=\"UTD.htm?22/49/23323\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/24\">",
"     24",
"    </a>",
"    ]. The AJCC head and neck stage system differs from that for cutaneous melanoma, in which prognosis depends upon the local, regional, and distant burden of disease. Staging begins at stage III as the most limited form of disease, to reflect the poor prognosis in these patients, and includes three subcategories of stage IV disease (IVA, IVB, and IVC), depending upon the local extent and presence of regional and distant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32356226\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32364903\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete surgical excision is the primary treatment for AJCC stage III and IVA mucosal melanomas of the head and neck if the lesion can be resected with negative margins. Surgery is not recommended as primary therapy for patients with lymph node involvement (IVB) or distant metastases (IVC), unless there is a need for local control of disease. Adjuvant radiotherapy should be considered if complete resection is possible. (See",
"    <a class=\"local\" href=\"#H32364415\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mucosal melanomas of the oral cavity are approached surgically in the same manner as squamous cell carcinomas at the same site. Local resection should be accompanied by appropriate reconstruction using free flaps for mandibular, soft tissue or structural defects. Similarly, mucosal melanoma of the larynx and pharynx should be managed by the appropriate surgical approach to achieve local control.",
"   </p>",
"   <p>",
"    Craniofacial resection has been used when tumor invades the skull base, either as part of the initial presentation or as an isolated local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Endoscopic resections are being performed more commonly and may be accomplished with less morbidity and equivalent local control [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite aggressive surgical management, local recurrence is very common [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/2,14,17,22\">",
"     2,14,17,22",
"    </a>",
"    ]. Factors associated with local recurrence include tumor size, incomplete resection, and vascular invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/14,30\">",
"     14,30",
"    </a>",
"    ]. The median time to first recurrence in the head and neck is 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/12,22\">",
"     12,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the initial site of relapse is frequently local or regional, such recurrence usually is a harbinger of disseminated disease with most patients dying of distant rather than uncontrolled local disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/2,12,21,31,32\">",
"     2,12,21,31,32",
"    </a>",
"    ]. Additional surgery can be considered for locally recurrent disease; however, the decision to proceed with re-resection for local or regional recurrence should be considered on a case-by-case basis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of nodal disease in sinonasal mucosal melanoma is less than 10 percent; thus elective lymph node dissection is not routinely recommended in these cases [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Melanoma arising from the oral cavity is associated with nodal disease in up to 25 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/14,17\">",
"       14,17",
"      </a>",
"      ] and some investigators recommend elective lymph node dissection in this subgroup of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/33\">",
"       33",
"      </a>",
"      ]. As in squamous cell carcinoma of the head and neck, the regional lymph nodes can be addressed at the same time as the primary resection, clearing the first and second echelons of nodes. When reconstruction using free flaps is required, the neck must be entered and clearance of the nodal disease can be considered.",
"     </li>",
"     <li>",
"      Therapeutic neck dissection in the setting of clinically evident disease can be accomplished with limited morbidity and may be performed for optimal regional control. However, no significant difference in five-year overall survival has been observed in patients with and without lymph node recurrence, suggesting that the treatment of the nodes should be based on need for local control and symptomatic treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sentinel lymph node biopsy does not have an established role in patients with mucosal melanoma of the head and neck, although identification of sentinel lymph nodes in patients with mucosal melanoma appears to be feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32364415\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) may have a role, either as an adjuvant following surgery or when surgery is not appropriate or feasible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local recurrence occurs in 29 to 79 percent of cases despite aggressive surgery and can be clinically devastating [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/2,17,31,36-38\">",
"       2,17,31,36-38",
"      </a>",
"      ]. Several series have reported an improvement in locoregional control with adjuvant RT although there is no demonstrable impact on survival [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/23,31,38-40\">",
"       23,31,38-40",
"      </a>",
"      ]. Such benefit however has not been observed in all series and the role of RT has not been definitively established in clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/14,41\">",
"       14,41",
"      </a>",
"      ]. Some centers recommend routine postoperative RT for those with palpable lymph nodes or the finding of extracapsular extension following wide local excision and neck dissection. RT is not used if lesions are close to the eye or central nervous system.",
"     </li>",
"     <li>",
"      Primary RT should be considered for patients who are not candidates for resection or when an adequate resection margin is not possible [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/31\">",
"       31",
"      </a>",
"      ]. Tumor control rates ranging from 61 to 85 percent have been reported with definitive RT in patients with mucosal melanomas arising from the head and neck [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. Analysis of these series is complicated by the selection bias toward the use of RT in patients with more extensive tumors and narrow or involved surgical margins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Optimal dosing and fractionation schedules have been established for RT either as primary therapy or as an adjuvant to surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=see_link\">",
"     \"Role of radiation therapy in the management of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32369728\">",
"    <span class=\"h3\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of metastatic mucosal melanoma of the head and neck is largely based upon experience in patients with cutaneous melanoma. (See",
"    <a class=\"local\" href=\"#H3306464\">",
"     'Systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32367986\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in patients with mucosal melanoma arising in the head and neck is generally poor, with reported five-year survival rates of 12 to 30 percent for primary lesions of the nasal cavity, oral cavity, and paranasal sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/12,14,44,45\">",
"     12,14,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3306331\">",
"    <span class=\"h1\">",
"     VULVOVAGINAL MELANOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanomas arising from the female urogenital tract occur primarily in the vulva and vagina (95 and 3 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/1\">",
"     1",
"    </a>",
"    ]; melanomas arising elsewhere in the urinary bladder, urethra, or cervix are rarer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/46-50\">",
"     46-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although vulvar melanomas account for less than 1 percent of all melanomas, they represent 10 percent of all malignant tumors involving the vulva [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. A subset of vulvar melanomas, particularly those arising from the outer, non-glabrous hair-bearing portion of the labia majora, may share common risk factors with cutaneous melanoma. Some vulvar melanomas may develop from contiguous nevi [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/53\">",
"     53",
"    </a>",
"    ]. Chronic inflammatory disease, viral infections, chemical irritants, and genetic factors have also been implicated as risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3306338\">",
"    <span class=\"h2\">",
"     Evaluation and staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with vulvovaginal melanoma commonly present with pruritus, vaginal bleeding, a vaginal discharge, dyspareunia, or a mass [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/55-60\">",
"     55-60",
"    </a>",
"    ]. Work-up for patients with vulvovaginal melanoma should include clinical assessment with pelvic examination, CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI of the primary site of disease, and CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PET imaging to assess for the presence of distant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1161823\">",
"    <span class=\"h3\">",
"     Vulvar melanoma staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gynecologic Oncology Group performed a prospective clinic-pathologic study of primary vulvar melanomas evaluating the predictive value of the microscopic staging systems described by Clark [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/62\">",
"     62",
"    </a>",
"    ], Breslow [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/63\">",
"     63",
"    </a>",
"    ], and Chung [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/64\">",
"     64",
"    </a>",
"    ], as well as the International Federation of Gynecology and Obstetrics (FIGO) system and the 1992 AJCC melanoma staging system. In this study, the AJCC cutaneous melanoma staging system was found to be the most significant predictor of recurrence-free survival in women with this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/65\">",
"     65",
"    </a>",
"    ]. A subsequent study assessed the 2002 modified AJCC melanoma staging system and confirmed the prognostic utility of the updated staging system to vulvar melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/66\">",
"     66",
"    </a>",
"    ]. The overall prognosis is a function of stage of disease at presentation. Outcomes are illustrated by the five-year relative survival rates in 223 women diagnosed between 1985 and 1989 in the United States based upon data in the National Cancer Data Base [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 0 &mdash; 77 percent",
"     </li>",
"     <li>",
"      Stage I &mdash; 70 percent",
"     </li>",
"     <li>",
"      Stage II &mdash; 50 percent",
"     </li>",
"     <li>",
"      Stage III &mdash; 48 percent",
"     </li>",
"     <li>",
"      Stage IV &mdash; 24 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, it is recommended that vulvar melanomas be staged according to the 2002 TNM system for melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1161832\">",
"    <span class=\"h3\">",
"     Vaginal melanoma staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;No staging system has been demonstrated to be a useful predictor of prognosis in vaginal melanoma, although tumor size (&lt;3 cm versus &gt; = 3 cm), has been shown to predict survival in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. In the absence of such a prognostic staging system for this disease, the previously described simplified clinical staging system can be used for the purposes of standardization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/11\">",
"     11",
"    </a>",
"    ]. In this system, stages I, II, and III correspond to clinically localized disease, regional lymph node involvement, and distant metastases, respectively.",
"   </p>",
"   <p>",
"    Because the majority of patients with mucosal melanoma present with localized stage I disease, the prognostic utility of this system is limited; however, due to its ease of use and broad applicability, it remains a reasonable staging system for patients with vaginal melanoma in the absence of a predictive alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32356678\">",
"    <span class=\"h2\">",
"     Locoregional management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with vulvovaginal melanoma ultimately develop distant metastatic disease regardless of the primary surgical procedure; thus, patient preference and quality of life considerations are critical factors in determining the extent of surgery for the initial management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1161488\">",
"    <span class=\"h3\">",
"     Vulvar melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wide local excision has generally replaced pelvic exenteration for vulvovaginal melanoma for women without evidence of distant metastases. Surgical management of vulvar melanomas should include resection of the primary tumor by wide local excision. Radical vulvectomy is reserved for large tumors primarily to obtain local disease control. Melanomas &lt;1 mm thick should be treated with 1 cm skin margins; if anatomically feasible, margins can be extended to 2 cm for thicker melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. The excision contains all layers of skin and subcutaneous tissues, extending to the muscular fascia below (",
"    <a class=\"graphic graphic_table graphicRef83489 \" href=\"UTD.htm?4/38/4718\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    More radical procedures are associated with significant morbidity. Although some series suggested improved local control with more aggressive surgical procedures, the impact of improved local control upon survival is limited by the concomitant development of distant metastases in the majority of cases. Available retrospective data suggest no difference in overall survival with more conservative wide local excision [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/66,67,71-76\">",
"     66,67,71-76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1161692\">",
"    <span class=\"h3\">",
"     Vaginal melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard management of women with vaginal melanoma involves wide local excision if possible. Achieving negative margins in these cases can be difficult without pelvic exenteration given the high frequency of multifocality and anatomic constraints. However, the impact of such radical surgery upon survival when compared with more conservative procedures (with or without radiotherapy) is unclear. Thus, surgery may be combined with RT in select cases. (See",
"    <a class=\"local\" href=\"#H32364415\">",
"     'Radiation therapy'",
"    </a>",
"    above.) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1161713\">",
"    <span class=\"h3\">",
"     Regional lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of sentinel nodes is feasible in women with vulvovaginal melanoma, but the role of this approach is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/54,78,79\">",
"     54,78,79",
"    </a>",
"    ]. While small series suggest a survival benefit for elective regional lymphadenectomy in patients with vulvar melanoma, a more contemporary study performed by the Gynecologic Oncology Group identified positive nodes as merely a prognostic factor along with tumor thickness. In this series, only 7 out of 56 patients undergoing a lymphadenectomy had positive nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/65\">",
"     65",
"    </a>",
"    ]. In addition, several studies have demonstrated that radical vulvectomy with bilateral inguinofemoral lymphadenectomy do not confer a survival benefit when compared with wide local excision alone for vulvar melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/76,80\">",
"     76,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32369763\">",
"    <span class=\"h3\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of metastatic vulvovaginal mucosal melanoma is largely based upon experience in patients with cutaneous melanoma. (See",
"    <a class=\"local\" href=\"#H3306464\">",
"     'Systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32369212\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite aggressive therapy, the prognosis remains poor for most patients with mucosal melanoma arising in the vulva or vagina. While patients with vulvar melanoma have five-year survival rates of 24 to 77 percent, those with vaginal melanoma have five-year survival rates of 5 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/57,69,81-85\">",
"     57,69,81-85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3306352\">",
"    <span class=\"h1\">",
"     ANORECTAL MELANOMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32357337\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorectal mucosal melanoma accounts for approximately 0.05 percent of all colorectal malignancies and 1 percent of all anal canal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/86\">",
"     86",
"    </a>",
"    ]. The site of origin is the rectum or anal canal in 42 and 33 percent of cases, respectively, while the primary site cannot be determined in the remainder. Although the risk factors for anorectal mucosal melanoma are not known, epidemiologic data suggest that there is an increased risk associated with human immunodeficiency virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506396#H1560506396\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of cases arise from the mucocutaneous junction; however, they can also arise from the skin of the anal verge, the transitional epithelium of the anal canal, or the rectal mucosa (",
"    <a class=\"graphic graphic_figure graphicRef62539 \" href=\"UTD.htm?14/30/14819\">",
"     figure 1",
"    </a>",
"    ). Identification of the primary site of disease is critical to separate anal cutaneous from anal mucosal melanomas.",
"   </p>",
"   <p>",
"    Patients typically present with bleeding, a mass, anorectal pain, or a change in bowel habits. Occasionally, melanoma is an incidental finding on pathologic evaluation of a hemorrhoidectomy or anal polyp specimen. Anorectal melanoma is pigmented in only one-third of cases. Most patients present with lesions that are &gt;2 mm thick. Regional lymph node involvement is found in approximately 60 percent of patients at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/1\">",
"     1",
"    </a>",
"    ], and distant metastases are present at diagnosis in about 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/89-94\">",
"     89-94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3306359\">",
"    <span class=\"h2\">",
"     Staging evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of patients with anorectal melanoma should include a rectal examination, rectal ultrasound, and CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PET imaging to assess for distant metastases.",
"   </p>",
"   <p>",
"    Anorectal melanoma is excluded from the AJCC staging system for anal cancers. Retrospective series have used a simple system in which localized disease only, regional lymph node involvement, and distant metastases are classified as stages I, II, and III, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with lymph node metastases or distant metastases at presentation have an especially poor prognosis. A review of 183 patients with anorectal mucosal melanoma identified in the Surveillance, Epidemiology and End Results (SEER) database found the following [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/89\">",
"     89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; median survival, 24 months; 5-year survival, 26.7 percent",
"     </li>",
"     <li>",
"      Stage II &mdash; median survival, 17 months; 5-year survival, 9.8 percent",
"     </li>",
"     <li>",
"      Stage III &mdash; median survival, 8 months; 5-year survival, 0 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors that may adversely affect prognosis in patients with localized disease include the presence of perineural invasion, tumor size and thickness, and the presence of amelanotic melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/90,91,97-99\">",
"     90,91,97-99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3306422\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32364273\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of surgery is to perform a negative margin, sphincter-sparing excision. Abdominoperineal resection is reserved for patients with bulky local disease and for carefully selected patients with local recurrence. Inguinal lymphadenectomy is reserved for patients with clinically apparent disease, given the morbidity of bilateral inguinal node dissection and lack of proven benefit from an elective dissection.",
"   </p>",
"   <p>",
"    Multiple retrospective series have looked at the impact of the extent of surgery on long-term outcomes. Some series suggested improved local control with abdominoperineal resection, a procedure accompanied by a high morbidity rate and functional limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/94,95,97\">",
"     94,95,97",
"    </a>",
"    ]; however, retrospective data suggest that there is no difference in overall survival with more conservative wide local excision [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/89,90,98,100,101\">",
"     89,90,98,100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of improved local control upon survival is limited. Most patients ultimately develop distant disease regardless of the primary surgical procedure; thus patient preference and quality of life considerations are critical in determining the extent of surgery.",
"   </p>",
"   <p>",
"    The most important factor in surgery appears to be the ability to achieve negative (R0) surgical resection margins [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/98,100\">",
"     98,100",
"    </a>",
"    ]. In a series of 251 cases from the Swedish National Cancer Registry, the five-year survival rates following surgical excision for those in whom an R0 resection was achieved was 19 percent, compared to 6 percent in those in whom a complete local excision was not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/100\">",
"     100",
"    </a>",
"    ]. On multivariate analysis, resection status and tumor stage were significantly associated with prognosis, but the type of resection (abdominoperineal resection or local excision) was not significant.",
"   </p>",
"   <p>",
"    Mesorectal, pelvic sidewall, and inguinal lymph nodes are at risk for involvement in anorectal mucosal melanoma. However, available data suggest that lymph node metastasis does not predict outcome in patients undergoing radical resection, and sentinel lymph node biopsy does not have an established role in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/98,102\">",
"     98,102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32364266\">",
"    <span class=\"h3\">",
"     Adjuvant radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant radiotherapy for anorectal melanoma may improve locoregional control despite a lack of demonstrable impact upon overall survival. Sphincter-sparing local excision followed by hypofractionated RT has been used as an alternative to APR in an effort to prevent local recurrence and preserve quality of life. In a series of 54 patients from MD Anderson Cancer Center treated over a 20 year period, this approach achieved local control in 82 percent of cases; however, the five-year overall survival rate was only 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32369798\">",
"    <span class=\"h3\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of metastatic anorectal melanoma is largely based upon experience in patients with cutaneous melanoma. (See",
"    <a class=\"local\" href=\"#H3306464\">",
"     'Systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32369205\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported five-year survival rates for patients with anorectal melanoma are approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/97,98,100,104\">",
"     97,98,100,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3306464\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32369551\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant immunotherapy with high-dose interferon alfa is a treatment option for patients with cutaneous melanoma and resected positive regional lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant immunotherapy for melanoma\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only data on the efficacy of systemic therapy for mucosal melanoma in the adjuvant setting come from a phase II randomized trial of interferon versus chemotherapy in Chinese patients with resected mucosal melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/105\">",
"     105",
"    </a>",
"    ]. In this trial, 189 patients who had undergone complete resection of a mucosal melanoma were randomly assigned to observation, postoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     MU/m2/day",
"    </span>",
"    for 5",
"    <span class=\"nowrap\">",
"     days/week",
"    </span>",
"    x 4 weeks followed by 9",
"    <span class=\"nowrap\">",
"     MU/m2",
"    </span>",
"    three times per week for 48 weeks) or chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    200",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    days 1 to 5 plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    25",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    days 1 to 3, every three weeks for six cycles).",
"   </p>",
"   <p>",
"    Preliminary results were presented at the 2012 American Society of Clinical Oncology (ASCO) meeting. With a median follow-up of 27 months, the median relapse-free survival was significantly prolonged with chemotherapy (20.8 versus 9.4 and 5.4 months, respectively, with interferon and observation). Estimated overall survival was also significantly increased (50 versus 41 and 21 months, respectively).",
"   </p>",
"   <p>",
"    These results require replication in a broader patient population before adjuvant chemotherapy can be considered a standard of care for Western patients with mucosal melanoma. This approach might be considered in carefully selected patients who have undergone a potentially curative resection, have no serious coexisting illness, and have the potential for long-term survival excluding their risk of melanoma related mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32357778\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the systemic treatment of patients with metastatic melanoma arising from a mucosal site are very limited, and treatments have been patterned after those used for metastatic melanoma from a cutaneous primary. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1160972\">",
"    <span class=\"h3\">",
"     Targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the molecular pathogenesis of mucosal melanoma has provided important insights that are leading to the development of targeted therapies for specific subsets of patients with metastatic disease. Approximately 10 percent of mucosal melanomas harbor activating mutations in BRAF and another 25 percent have somatic mutations or amplification of KIT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"     \"Molecularly targeted therapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate, a small molecule inhibitor of KIT and other tyrosine kinases, demonstrated this agent to be ineffective in a molecularly unselected patient population with advanced melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. However, several case reports have demonstrated rapid and durable tumor responses to KIT inhibition in patients with melanoma harboring KIT mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/111,112\">",
"     111,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three subsequent phase II trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    have been conducted; unlike the prior trials, each of these studies required the presence of melanoma harboring somatic alteration of KIT for eligibility.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 6 of 25 evaluable patients had a radiographic response [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/106\">",
"       106",
"      </a>",
"      ]. Two patients had durable complete responses, two patients had durable partial responses, and two patients had transient partial responses. All six patients who responded had either an L576P (exon 11) or a K642E (exon 13) KIT mutation. Both patients who had a complete response had exon 11 L576P mutations with concurrent amplification.",
"     </li>",
"     <li>",
"      In another series, 43 patients with a KIT alteration were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/113\">",
"       113",
"      </a>",
"      ]. A partial response was observed in 10 cases (23 percent); overall, 18 patients had evidence of tumor regression. One patient with a KIT amplification without a mutation responded. Of the patients with KIT mutations, only patients with mutations in exons 11 and 13 responded.",
"     </li>",
"     <li>",
"      Interim results were presented at the 2009 International Melanoma Congress from a study of 20 patients with KIT abnormalities in their tumors, including 10 with tumors harboring KIT mutations and 10 with tumors harboring KIT amplification alone. Five responses were seen (25 percent), but no responses were observed in the 10 patients whose tumors harbored KIT amplification alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with KIT mutant melanoma have also been reported to respond to other targeted inhibitors of KIT such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/114\">",
"     114",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/115\">",
"     115",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/116\">",
"     116",
"    </a>",
"    ]. Notably, all of these patients had KIT mutations involving exon 11 or 13.",
"   </p>",
"   <p>",
"    Testing for such alterations should be considered in all patients with advanced mucosal melanoma. A trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    should be considered in patients with advanced mucosal melanoma harboring a BRAF mutation. If a KIT mutation is detected, patients should be considered for enrolment on clinical trials with agents targeting c-Kit [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/106,113,117\">",
"     106,113,117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100473013#H100473013\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'Kit inhibition'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1160979\">",
"    <span class=\"h3\">",
"     Anti-CTLA4 immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-CTLA4 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    has been shown to significantly prolong survival in some patients with cutaneous melanoma. Currently, there are no data in patients with metastatic mucosal melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H175769012#H175769012\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Ipilimumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1160865\">",
"    <span class=\"h3\">",
"     Biochemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective series suggest that response rates for patients with metastatic mucosal melanoma to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based biochemotherapy regimens are similar to those in patients with cutaneous disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=see_link\">",
"     \"Cytotoxic chemotherapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In 18 patients with metastatic anorectal mucosal melanoma,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy was combined with interferon alpha-2b",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interleukin-2 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/118\">",
"       118",
"      </a>",
"      ]. Eight patients (44 percent) achieved major responses, including two (11 percent) complete responses. With a median follow-up time of 12.2 months (range, 3.5 to 43.7 months), the median time to progression of the 15 patients available for follow-up was 6 months and the median overall survival was 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In another series, 11 patients with metastatic vulvovaginal mucosal melanoma were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy plus interferon alpha-2b",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interleukin-2 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/119\">",
"       119",
"      </a>",
"      ]. Four patients (36 percent) achieved a partial response. With a median follow-up of 10 months, the median time to progression was 3 months and the median overall survival was 10 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a third series, 15 patients with metastatic mucosal melanoma of the head and neck were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based biochemotherapy regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/120\">",
"       120",
"      </a>",
"      ]. After a median follow-up of 13 months, 3 patients (20 percent) achieved a partial response, and 4 patients (27 percent) had complete response. The median time to disease progression for all 15 patients was 10 months, and the median overall survival was 22 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32369859\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete resection of mucosal melanoma is challenging due to the frequent multifocal presentation as well as anatomic considerations. While radiotherapy can lead to effective local control of unresectable disease, such therapy is limited by tissue tolerance and toxicity. Thus, alternative local therapies are needed.",
"   </p>",
"   <p>",
"    The topical immune modifier",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    has been used experimentally to treat lentigo maligna and cutaneous metastases from invasive melanoma. In three patients with recurrent mucosal melanoma, topical treatment with imiquimod resulted in local control of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/121\">",
"     121",
"    </a>",
"    ]. However, regional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distant metastases developed in all three cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathologic characteristics of melanoma\", section on 'In situ melanoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prognosis of basal cell carcinoma\", section on 'Imiquimod'",
"    </a>",
"    .) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/58/4010/abstract/122-126\">",
"     122-126",
"    </a>",
"    ]. This approach remains experimental and should not be used outside a protocol setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3306471\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies detailing the optimal approach to surveillance following treatment of mucosal melanoma. The approach has been based upon extrapolation from patients with cutaneous melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link&amp;anchor=H7#H7\">",
"     \"Staging work-up and surveillance after treatment of melanoma\", section on 'Surveillance after treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3306478\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanomas may arise from the mucosal epithelium lining the respiratory, alimentary, and genitourinary tracts, all of which contain melanocytes, as well as from the skin. The most common sites of involvement are the head and neck, vulvovaginal, and anorectal regions. Mucosal melanomas generally carry a worse prognosis than those arising from cutaneous sites, with most patients developing recurrent and disseminated disease.",
"   </p>",
"   <p>",
"    Mucosal melanomas are rare. Treatment recommendations for patients with mucosal melanoma are based almost exclusively upon small, retrospective studies that include heterogeneous patient populations treated at single institutions over a long time period.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standard initial management for locoregionally confined mucosal melanoma is complete wide local surgical resection, which offers the best chance for long-term survival. Most patients will ultimately develop distant metastatic disease regardless of the achievement of local control with initial treatment. Thus, patient preferences as well as quality of life considerations are critical in determining the extent of surgery for resection of the primary lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mucosal melanomas of the head and neck mucosal are approached surgically in the same manner as squamous cell carcinomas at the same site. (See",
"      <a class=\"local\" href=\"#H32356226\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More conservative wide local excision has generally replaced pelvic exenteration for vulvovaginal melanoma and abdominoperineal resection for anorectal melanoma. (See",
"      <a class=\"local\" href=\"#H32356678\">",
"       'Locoregional management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3306422\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In carefully selected patients, radiation therapy may be an alternative to control local disease when a complete resection is not feasible. Adjuvant radiation therapy may also decrease the incidence of local recurrences in carefully selected patients, although no impact on survival has been demonstrated. (See",
"      <a class=\"local\" href=\"#H32364415\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32356678\">",
"       'Locoregional management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32364266\">",
"       'Adjuvant radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The approach to management of systemic metastases from a mucosal melanoma is based upon the treatment of metastatic cutaneous disease. Advances in targeted therapy and immunotherapy for metastatic melanoma may offer important treatment options as more data become available. The biology of mucosal melanoma makes therapeutic strategies such as KIT inhibition particularly attractive within the context of a clinical trial. (See",
"      <a class=\"local\" href=\"#H32357778\">",
"       'Metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/1\">",
"      Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/2\">",
"      Meleti M, Leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck 2008; 30:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/3\">",
"      Rapini RP, Golitz LE, Greer RO Jr, et al. Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer 1985; 55:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/4\">",
"      Sutherland CM, Chmiel JS, Henson DE, Winchester DP. Patient characteristics, methods of diagnosis, and treatment of mucous membrane melanoma in the United States of America. J Am Coll Surg 1994; 179:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/5\">",
"      Pandey M, Mathew A, Abraham EK, et al. Primary malignant melanoma of the mucous membranes. Eur J Surg Oncol 1998; 24:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/6\">",
"      Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol 2007; 56:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/7\">",
"      McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer 2005; 103:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/8\">",
"      Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988-93. Cancer Causes Control 1997; 8:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/9\">",
"      Lotem M, Anteby S, Peretz T, et al. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol Oncol 2003; 88:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/10\">",
"      Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Canc Netw 2012; 10:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/11\">",
"      Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg 1970; 120:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/12\">",
"      Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 1997; 80:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/13\">",
"      Nandapalan V, Roland NJ, Helliwell TR, et al. Mucosal melanoma of the head and neck. Clin Otolaryngol Allied Sci 1998; 23:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/14\">",
"      Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002; 24:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/15\">",
"      McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol 2008; 44:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/16\">",
"      DeMatos P, Tyler DS, Seigler HF. Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol 1998; 5:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/17\">",
"      Bachar G, Loh KS, O'Sullivan B, et al. Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital. Head Neck 2008; 30:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/18\">",
"      Johnson IJ, Warfield AT, Smallman LA, Watkinson JC. Primary malignant melanoma of the pharynx. J Laryngol Otol 1994; 108:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/19\">",
"      Amin HH, Petruzzelli GJ, Husain AN, Nickoloff BJ. Primary malignant melanoma of the larynx. Arch Pathol Lab Med 2001; 125:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/20\">",
"      Archer HA, Owen WJ. Primary malignant melanoma of the esophagus. Dis Esophagus 2000; 13:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/21\">",
"      Stern SJ, Guillamondegui OM. Mucosal melanoma of the head and neck. Head Neck 1991; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/22\">",
"      Lee SP, Shimizu KT, Tran LM, et al. Mucosal melanoma of the head and neck: the impact of local control on survival. Laryngoscope 1994; 104:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/23\">",
"      Moreno MA, Roberts DB, Kupferman ME, et al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer 2010; 116:2215.",
"     </a>",
"    </li>",
"    <li>",
"     Mucosal melanoma of the Head and Neck. In: AJCC Cancer Staging Manual, Seventh, Springer, 2010. p.97.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/25\">",
"      Prasad ML, Patel SG, Huvos AG, et al. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer 2004; 100:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/26\">",
"      Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol 2003; 27:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/27\">",
"      Ganly I, Patel SG, Singh B, et al. Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study. Arch Otolaryngol Head Neck Surg 2006; 132:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/28\">",
"      Lund VJ, Howard DJ, Harding L, Wei WI. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope 1999; 109:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/29\">",
"      Hanna E, DeMonte F, Ibrahim S, et al. Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg 2009; 135:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/30\">",
"      Panje WR, Moran WJ. Melanoma of the upper aerodigestive tract: a review of 21 cases. Head Neck Surg 1986; 8:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/31\">",
"      Krengli M, Masini L, Kaanders JH, et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2006; 65:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/32\">",
"      Loree TR, Mullins AP, Spellman J, et al. Head and neck mucosal melanoma: a 32-year review. Ear Nose Throat J 1999; 78:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/33\">",
"      Medina JE, Ferlito A, Pellitteri PK, et al. Current management of mucosal melanoma of the head and neck. J Surg Oncol 2003; 83:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/34\">",
"      St&aacute;rek I, Koranda P, Benes P. Sentinel lymph node biopsy: A new perspective in head and neck mucosal melanoma? Melanoma Res 2006; 16:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/35\">",
"      Baptista P, Garcia Velloso MJ, Salvinelli F, Casale M. Radioguided surgical strategy in mucosal melanoma of the nasal cavity. Clin Nucl Med 2008; 33:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/36\">",
"      Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003; 129:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/37\">",
"      Nakashima JP, Vi&eacute;gas CM, Fassizoli AL, et al. Postoperative adjuvant radiation therapy in the treatment of primary head and neck mucosal melanomas. ORL J Otorhinolaryngol Relat Spec 2008; 70:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/38\">",
"      Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer 2005; 103:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/39\">",
"      Yii NW, Eisen T, Nicolson M, et al. Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century. Clin Oncol (R Coll Radiol) 2003; 15:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/40\">",
"      Benlyazid A, Thariat J, Temam S, et al. Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. Arch Otolaryngol Head Neck Surg 2010; 136:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/41\">",
"      Wu AJ, Gomez J, Zhung JE, et al. Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol 2010; 33:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/42\">",
"      Yanagi T, Mizoe JE, Hasegawa A, et al. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2009; 74:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/43\">",
"      Wada H, Nemoto K, Ogawa Y, et al. A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys 2004; 59:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/44\">",
"      Cheng YF, Lai CC, Ho CY, et al. Toward a better understanding of sinonasal mucosal melanoma: clinical review of 23 cases. J Chin Med Assoc 2007; 70:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/45\">",
"      Dauer EH, Lewis JE, Rohlinger AL, et al. Sinonasal melanoma: a clinicopathologic review of 61 cases. Otolaryngol Head Neck Surg 2008; 138:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/46\">",
"      Katz EE, Suzue K, Wille MA, et al. Primary malignant melanoma of the urethra. Urology 2005; 65:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/47\">",
"      Kojima T, Tanaka T, Yoshimi N, Mori H. Primary malignant melanoma of the urinary bladder. Arch Pathol Lab Med 1992; 116:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/48\">",
"      Khalbuss WE, Hossain M, Elhosseiny A. Primary malignant melanoma of the urinary bladder diagnosed by urine cytology: a case report. Acta Cytol 2001; 45:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/49\">",
"      Clark KC, Butz WR, Hapke MR. Primary malignant melanoma of the uterine cervix: case report with world literature review. Int J Gynecol Pathol 1999; 18:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/50\">",
"      Cantuaria G, Angioli R, Nahmias J, et al. Primary malignant melanoma of the uterine cervix: case report and review of the literature. Gynecol Oncol 1999; 75:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/51\">",
"      Creasman WT, Phillips JL, Menck HR. A survey of hospital management practices for vulvar melanoma. J Am Coll Surg 1999; 188:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/52\">",
"      Stang A, Streller B, Eisinger B, J&ouml;ckel KH. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecol Oncol 2005; 96:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/53\">",
"      Ragnarsson-Olding BK, Kanter-Lewensohn LR, Lagerl&ouml;f B, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathologic features. Cancer 1999; 86:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/54\">",
"      Wechter ME, Gruber SB, Haefner HK, et al. Vulvar melanoma: a report of 20 cases and review of the literature. J Am Acad Dermatol 2004; 50:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/55\">",
"      Piura B, Egan M, Lopes A, Monaghan JM. Malignant melanoma of the vulva: a clinicopathologic study of 18 cases. J Surg Oncol 1992; 50:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/56\">",
"      Piura B, Rabinovich A, Dgani R. Malignant melanoma of the vulva: report of six cases and review of the literature. Eur J Gynaecol Oncol 1999; 20:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/57\">",
"      Verschraegen CF, Benjapibal M, Supakarapongkul W, et al. Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer 2001; 11:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/58\">",
"      Piura B, Rabinovich A, Yanai-Inbar I. Primary malignant melanoma of the vagina: case report and review of literature. Eur J Gynaecol Oncol 2002; 23:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/59\">",
"      Sugiyama VE, Chan JK, Shin JY, et al. Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol 2007; 110:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/60\">",
"      Borazjani G, Prem KA, Okagaki T, et al. Primary malignant melanoma of the vagina: a clinicopathological analysis of 10 cases. Gynecol Oncol 1990; 37:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/61\">",
"      Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/62\">",
"      Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/63\">",
"      Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/64\">",
"      Chung AF, Woodruff JM, Lewis JL Jr. Malignant melanoma of the vulva: A report of 44 cases. Obstet Gynecol 1975; 45:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/65\">",
"      Phillips GL, Bundy BN, Okagaki T, et al. Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group. Cancer 1994; 73:2626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/66\">",
"      Moxley KM, Fader AN, Rose PG, et al. Malignant melanoma of the vulva: an extension of cutaneous melanoma? Gynecol Oncol 2011; 122:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/67\">",
"      Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature. Am J Obstet Gynecol 1998; 178:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/68\">",
"      Petru E, Nagele F, Czerwenka K, et al. Primary malignant melanoma of the vagina: long-term remission following radiation therapy. Gynecol Oncol 1998; 70:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/69\">",
"      Irvin WP Jr, Legallo RL, Stoler MH, et al. Vulvar melanoma: a retrospective analysis and literature review. Gynecol Oncol 2001; 83:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/70\">",
"      Trimble EL. Melanomas of the vulva and vagina. Oncology (Williston Park) 1996; 10:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/71\">",
"      DeMatos P, Tyler D, Seigler HF. Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center. Surgery 1998; 124:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/72\">",
"      Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer 1999; 86:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/73\">",
"      Miner TJ, Delgado R, Zeisler J, et al. Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol 2004; 11:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/74\">",
"      Suwandinata FS, Bohle RM, Omwandho CA, et al. Management of vulvar melanoma and review of the literature. Eur J Gynaecol Oncol 2007; 28:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/75\">",
"      Bradgate MG, Rollason TP, McConkey CC, Powell J. Malignant melanoma of the vulva: a clinicopathological study of 50 women. Br J Obstet Gynaecol 1990; 97:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/76\">",
"      Trimble EL, Lewis JL Jr, Williams LL, et al. Management of vulvar melanoma. Gynecol Oncol 1992; 45:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/77\">",
"      Irvin WP Jr, Bliss SA, Rice LW, et al. Malignant melanoma of the vagina and locoregional control: radical surgery revisited. Gynecol Oncol 1998; 71:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/78\">",
"      de Hullu JA, Hollema H, Hoekstra HJ, et al. Vulvar melanoma: is there a role for sentinel lymph node biopsy? Cancer 2002; 94:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/79\">",
"      Dhar KK, DAS N, Brinkman DA, et al. Utility of sentinel node biopsy in vulvar and vaginal melanoma: report of two cases and review of the literature. Int J Gynecol Cancer 2007; 17:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/80\">",
"      Jaramillo BA, Ganjei P, Averette HE, et al. Malignant melanoma of the vulva. Obstet Gynecol 1985; 66:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/81\">",
"      G&ouml;kaslan H, Simanolu A, Pekin T, et al. Primary malignant melanoma of the vagina: a case report and review of the current treatment options. Eur J Obstet Gynecol Reprod Biol 2005; 121:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/82\">",
"      Bonner JA, Perez-Tamayo C, Reid GC, et al. The management of vaginal melanoma. Cancer 1988; 62:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/83\">",
"      Weinstock MA. Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol 1994; 171:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/84\">",
"      Creasman WT, Phillips JL, Menck HR. The National Cancer Data Base report on cancer of the vagina. Cancer 1998; 83:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/85\">",
"      Frumovitz M, Etchepareborda M, Sun CC, et al. Primary malignant melanoma of the vagina. Obstet Gynecol 2010; 116:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/86\">",
"      Cagir B, Whiteford MH, Topham A, et al. Changing epidemiology of anorectal melanoma. Dis Colon Rectum 1999; 42:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/87\">",
"      Cot&eacute; TR, Sobin LH. Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin. Melanoma Res 2009; 19:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/88\">",
"      Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/89\">",
"      Iddings DM, Fleisig AJ, Chen SL, et al. Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol 2010; 17:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/90\">",
"      Pessaux P, Pocard M, Elias D, et al. Surgical management of primary anorectal melanoma. Br J Surg 2004; 91:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/91\">",
"      Cooper PH, Mills SE, Allen MS Jr. Malignant melanoma of the anus: report of 12 patients and analysis of 255 additional cases. Dis Colon Rectum 1982; 25:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/92\">",
"      Weinstock MA. Epidemiology and prognosis of anorectal melanoma. Gastroenterology 1993; 104:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/93\">",
"      Goldman S, Glimelius B, P&aring;hlman L. Anorectal malignant melanoma in Sweden. Report of 49 patients. Dis Colon Rectum 1990; 33:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/94\">",
"      Ross M, Pezzi C, Pezzi T, et al. Patterns of failure in anorectal melanoma. A guide to surgical therapy. Arch Surg 1990; 125:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/95\">",
"      Roumen RM. Anorectal melanoma in The Netherlands: a report of 63 patients. Eur J Surg Oncol 1996; 22:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/96\">",
"      Kubo K, Fujiyoshi T, Yokoyama MM, et al. Lack of association of Borna disease virus and human T-cell leukemia virus type 1 infections with psychiatric disorders among Japanese patients. Clin Diagn Lab Immunol 1997; 4:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/97\">",
"      Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum 1995; 38:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/98\">",
"      Yeh JJ, Shia J, Hwu WJ, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg 2006; 244:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/99\">",
"      Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 2002; 20:4555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/100\">",
"      Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. Br J Surg 2010; 97:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/101\">",
"      Droesch JT, Flum DR, Mann GN. Wide local excision or abdominoperineal resection as the initial treatment for anorectal melanoma? Am J Surg 2005; 189:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/102\">",
"      Tien HY, McMasters KM, Edwards MJ, Chao C. Sentinel lymph node metastasis in anal melanoma: a case report. Int J Gastrointest Cancer 2002; 32:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/103\">",
"      Kelly P, Zagars GK, Cormier JN, et al. Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: A 20-year experience. Cancer 2011; 117:4747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/104\">",
"      Thibault C, Sagar P, Nivatvongs S, et al. Anorectal melanoma--an incurable disease? Dis Colon Rectum 1997; 40:661.",
"     </a>",
"    </li>",
"    <li>",
"     Lian B, Mao L, Cui CL, et al. Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma. J Clin Oncol 2012; 30: (suppl; abstr 8506).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/106\">",
"      Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/107\">",
"      Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24:4340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/108\">",
"      Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005; 92:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/109\">",
"      Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006; 106:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/110\">",
"      Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008; 99:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/111\">",
"      Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/112\">",
"      Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008; 21:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/113\">",
"      Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29:2904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/114\">",
"      Quint&aacute;s-Cardama A, Lazar AJ, Woodman SE, et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008; 5:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/115\">",
"      Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009; 8:2079.",
"     </a>",
"    </li>",
"    <li>",
"     Zhu Y, Si L, Kong Y, et al. Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 2009; 27: (suppl: abstract e20017)",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/117\">",
"      Fisher DE, Barnhill R, Hodi FS, et al. Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res 2010; 23:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/118\">",
"      Kim KB, Sanguino AM, Hodges C, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 2004; 100:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/119\">",
"      Harting MS, Kim KB. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res 2004; 14:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/120\">",
"      Bartell HL, Bedikian AY, Papadopoulos NE, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 2008; 30:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/121\">",
"      Smyth EC, Flavin M, Pulitzer MP, et al. Treatment of locally recurrent mucosal melanoma with topical imiquimod. J Clin Oncol 2011; 29:e809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/122\">",
"      Hyde MA, Hadley ML, Tristani-Firouzi P, et al. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol 2012; 148:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/123\">",
"      Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002; 205:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/124\">",
"      Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003; 139:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/125\">",
"      Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 Suppl 66:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/58/4010/abstract/126\">",
"      Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol 2009; 160:994.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16904 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4010=[""].join("\n");
var outline_f3_58_4010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3306478\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3306289\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32370021\">",
"      MUCOSAL VERSUS CUTANEOUS MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32370278\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32370271\">",
"      Biology and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3306310\">",
"      MUCOSAL MELANOMA OF THE HEAD AND NECK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32357298\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3306317\">",
"      Evaluation and staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32356226\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32364903\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32364415\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32369728\">",
"      - Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32367986\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3306331\">",
"      VULVOVAGINAL MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3306338\">",
"      Evaluation and staging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1161823\">",
"      - Vulvar melanoma staging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1161832\">",
"      - Vaginal melanoma staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32356678\">",
"      Locoregional management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1161488\">",
"      - Vulvar melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1161692\">",
"      - Vaginal melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1161713\">",
"      - Regional lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32369763\">",
"      - Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32369212\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3306352\">",
"      ANORECTAL MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32357337\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3306359\">",
"      Staging evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3306422\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32364273\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32364266\">",
"      - Adjuvant radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32369798\">",
"      - Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32369205\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3306464\">",
"      SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32369551\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32357778\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1160972\">",
"      - Targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1160979\">",
"      - Anti-CTLA4 immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1160865\">",
"      - Biochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32369859\">",
"      EXPERIMENTAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3306471\">",
"      SURVEILLANCE AFTER SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3306478\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16904\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16904|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/30/14819\" title=\"figure 1\">",
"      Anatomy of the anus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16904|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/41/38555\" title=\"table 1\">",
"      TNM staging muc melanoma HN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/49/23323\" title=\"table 2\">",
"      Muc melanoma HN stage group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/38/4718\" title=\"table 3\">",
"      TNM staging system vulvar melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=related_link\">",
"      Cytotoxic chemotherapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=related_link\">",
"      Role of radiation therapy in the management of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=related_link\">",
"      Staging work-up and surveillance after treatment of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_58_4011="Classic Li-Fraumeni syndrome - Diagnostic criteria";
var content_f3_58_4011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classic Li-Fraumeni syndrome",
"    <sup>",
"     [1]",
"    </sup>",
"    - Diagnostic criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        All of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A proband with sarcoma diagnosed before age 45 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A first-degree relative with any cancer before age 45 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A first- or second-degree relative with any cancer before age 45 years or a sarcoma at any age",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4011=[""].join("\n");
var outline_f3_58_4011=null;
var title_f3_58_4012="Catheterization mitral stenosis";
var content_f3_58_4012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Cardiac catheterization in mitral stenosis (MS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that cardiac catheterization for hemodynamic evaluation is",
"useful in patients with MS in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the severity of MS if noninvasive tests are not conclusive or there is a discrepancy between the results of noninvasive tests and clinical findings related to the severity of MS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; When there is a discrepancy between mitral valve area and the Doppler-derived mean gradient; catheterization should include left ventriculography to evaluate the severity of mitral regurgitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or",
"opinion is in favor of usefulness of cardiac catheterization for",
"hemodynamic evaluation in patients with MS in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the exercise-induced hemodynamic response of the pulmonary artery and left atrial pressures when there is a discrepancy between clinical symptoms and hemodynamics at rest.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the cause of severe pulmonary arterial hypertension if it is out of proportion to the severity of MS determined by noninvasive testing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that cardiac catheterization for hemodynamic",
"evaluation in patients with MS is not useful in in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess mitral valve hemodynamics when two-dimensional and Doppler echocardiographic findings are consistent with clinical findings.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4012=[""].join("\n");
var outline_f3_58_4012=null;
var title_f3_58_4013="Clin char Rx opts chondro";
var content_f3_58_4013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of clinical characteristics and therapeutic options in all subtypes of chondrosarcoma of bone",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Conventional central chondrosarcoma",
"      </td>",
"      <td class=\"subtitle1\">",
"       Conventional peripheral chondrosarcoma",
"      </td>",
"      <td class=\"subtitle1\">",
"       Periosteal chondrosarcoma",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dedifferentiated chondrosarcoma",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mesenchymal chondrosarcoma",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clear cell chondrosarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Percent of all chondrosarcomas",
"      </td>",
"      <td>",
"       &sim;75 percent",
"      </td>",
"      <td>",
"       &sim;10 percent",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &sim;10 percent",
"      </td>",
"      <td>",
"       &lt;2 percent",
"      </td>",
"      <td>",
"       &lt;2 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Precursor lesion",
"      </td>",
"      <td>",
"       Enchondroma (up to 40 percent?)",
"      </td>",
"      <td>",
"       Osteochondromas (100 percent)",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Conventional chondrosarcoma",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       None",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Occurrence within syndrome",
"      </td>",
"      <td>",
"       Enchondromatosis (Ollier disease)",
"      </td>",
"      <td>",
"       Multiple osteochondromas (MO)",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Rarely in MOs or enchondromatosis",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       None",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Age",
"      </td>",
"      <td>",
"       &gt;50 years",
"      </td>",
"      <td>",
"       Younger than central chondrosarcoma",
"      </td>",
"      <td>",
"       Peak at fourth decade",
"      </td>",
"      <td>",
"       Median age 59 years",
"      </td>",
"      <td>",
"       Any age (peak at second to third decade)",
"      </td>",
"      <td>",
"       Any age (peak in third to fifth decade)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Preferential location",
"      </td>",
"      <td>",
"       Pelvis, proximal femur, proximal humerus, distal femur, ribs",
"      </td>",
"      <td>",
"       Pelvis, shoulder girdle bones",
"      </td>",
"      <td>",
"       Distal femur and humerus",
"      </td>",
"      <td>",
"       Femur and pelvis",
"      </td>",
"      <td>",
"       <p>",
"        65 to 86 percent skeleton (jawbones, ribs, ilium, vertebrae)",
"       </p>",
"       <p>",
"        14 to 43 percent extraosseous (meninges)",
"       </p>",
"      </td>",
"      <td>",
"       Epiphysis of humeral or femoral head",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Histological grading",
"      </td>",
"      <td colspan=\"2\">",
"       Grade 1 to 3",
"      </td>",
"      <td rowspan=\"2\">",
"       Prognosis usually good despite worrisome histology",
"      </td>",
"      <td>",
"       High grade",
"      </td>",
"      <td>",
"       High grade",
"      </td>",
"      <td>",
"       Low grade",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Survival",
"      </td>",
"      <td colspan=\"2\">",
"       <p>",
"        Grade 1: 83 percent",
"       </p>",
"       <p>",
"        Grade 2: 64 percent",
"       </p>",
"       <p>",
"        Grade 3: 29 percent",
"       </p>",
"       <p>",
"        All at ten years",
"       </p>",
"      </td>",
"      <td>",
"       24 percent at five years",
"      </td>",
"      <td>",
"       28 percent at ten years",
"      </td>",
"      <td>",
"       89 percent at ten years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Sensitivity to conventional chemotherapy",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Uncertain",
"      </td>",
"      <td>",
"       Possibly, if high percentage round cells",
"      </td>",
"      <td>",
"       None",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Sensitivity to radiotherapy",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       Possibly high",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_58_4013=[""].join("\n");
var outline_f3_58_4013=null;
var title_f3_58_4014="Contents: Soft tissue rheumatic disease";
var content_f3_58_4014=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Soft tissue rheumatic disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Soft tissue rheumatic disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Carpal tunnel syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/15/42230\">",
"           Clinical manifestations and diagnosis of carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/22/23911\">",
"           Etiology of carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/3/32822\">",
"           Surgery for carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/62/44008\">",
"           Treatment of carpal tunnel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Joint protection and rehabilitation programs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/41/32407\">",
"           Joint protection program for the lower limb",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/24/30085\">",
"           Joint protection program for the neck",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/40/37508\">",
"           Joint protection program for the upper limb",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/3/35896\">",
"           Overview of joint protection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/54/39783\">",
"           Dupuytren's contracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/24/1418\">",
"           Evaluation of the patient with neck pain and cervical spine disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41223\">",
"           Ganglia and nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/9/2201\">",
"           Major causes of musculoskeletal chest pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/44/19141\">",
"           Trigger finger (stenosing flexor tenosynovitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/40/27270\">",
"           de Quervain's tenosynovitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Soft tissue inflammation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/45/14041\">",
"           Bursitis: An overview of clinical manifestations, diagnosis, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/48/28422\">",
"           Knee bursitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/30/42472\">",
"           Overview of soft tissue rheumatic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/40/44681\">",
"           Plantar fasciitis and other causes of heel pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/30/33256\">",
"           Septic bursitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/33/18966\">",
"           Trochanteric bursitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sports injuries",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/40/44681\">",
"           Plantar fasciitis and other causes of heel pain",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-E1F35D45B6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_58_4014=[""].join("\n");
var outline_f3_58_4014=null;
var title_f3_58_4015="Contents: Depressive disorders";
var content_f3_58_4015=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Depressive disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Depressive disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antidepressant medication",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/33/26135\">",
"           Antidepressant medication in adults: Switching and discontinuing medication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/18/5417\">",
"           Atypical antidepressants: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/48/43783\">",
"           Effect of antidepressants on suicide risk in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7574\">",
"           Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/0/5129\">",
"           Serotonin modulators: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/28/5578\">",
"           Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/63/2039\">",
"           Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/56/31626\">",
"           Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/20/36169\">",
"           Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/3/17464\">",
"           Unipolar depression in adults: Anxiolytics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/34/27175\">",
"           Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/39/9850\">",
"           Unipolar depression in adults: Continuation and maintenance treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38745\">",
"           Use of psychotropic medications in breastfeeding women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bipolar disorder",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43065\">",
"           Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/11/19639\">",
"           Bipolar disorder in adults: Epidemiology and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/9/27802\">",
"           Bipolar disorder in adults: Maintenance treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/3/44088\">",
"           Bipolar disorder in adults: Pharmacotherapy for acute depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/8/38026\">",
"           Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Depression",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/57/5017\">",
"           Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/57/43928\">",
"           Catatonia in adults: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/13/11481\">",
"           Clinical manifestations and diagnosis of depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28328\">",
"           Depression in adults: Psychodynamic psychotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/13/16601\">",
"           Depression in adults: Supportive psychotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/2/29735\">",
"           Depression in pregnant women: Clinical features and consequences",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/0/28682\">",
"           Depression in pregnant women: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/37/39514\">",
"           Diagnosis and management of late-life depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/38/18025\">",
"           Family and couples therapy for treating depressed adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31190\">",
"           Grief and bereavement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/8/40074\">",
"           Initial treatment of depression in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/16/17674\">",
"           Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/20/4425\">",
"           Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/24/8584\">",
"           Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/21/41305\">",
"           Overview of electroconvulsive therapy (ECT) for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27242\">",
"           Overview of idiopathic environmental intolerance (multiple chemical sensitivity)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/11/20666\">",
"           Postpartum blues and depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/25/22936\">",
"           Seasonal affective disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/8/10377\">",
"           Suicidal ideation and behavior in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13128\">",
"           Technique for performing electroconvulsive therapy (ECT) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/61/27609\">",
"           Treatment of resistant depression in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37481\">",
"           Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/30/6633\">",
"           Unipolar depression in adults: Overview of neuromodulation procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/19/38201\">",
"           Unipolar depression in adults: Prognosis and course of illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/50/17192\">",
"           Unipolar depression in adults: Treatment with lithium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31993\">",
"           Unipolar depression in adults: Treatment with second-generation antipsychotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/62/5097\">",
"           Unipolar depression in adults: Treatment with surgical approaches",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/18/16682\">",
"           Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41416\">",
"           Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4105\">",
"           Unipolar major depression with psychotic features: Acute treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/15/5368\">",
"           Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8055\">",
"           Unipolar major depression with psychotic features: Maintenance treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/26/26025\">",
"           Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/12/35015\">",
"           Unipolar minor depression in adults: Management and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/40/4745\">",
"           Using scales to monitor symptoms and treatment of depression (measurement based care)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E333A85260-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_58_4015=[""].join("\n");
var outline_f3_58_4015=null;
